Official Title:  A Prospective, Randomized, Double-masked, Active Comparator-
controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of 
Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Neovascular 
(Wet) Age-related Macular Degeneration (wAMD)
Study ID: [REMOVED]
Document Date:  Protocol Version 2.0, 16 March 2022
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
1 CLINICAL STUDY PROTOCOL  
Protocol Title:  A Prospective, Randomized, Double -masked, Active 
Comparator-controlled, M ulti-center, T wo-arm, P hase 3 Study to 
Evaluate the Efficacy and S afety of I ntravitreal KSI -301 
Compared with I ntravitreal Aflibercept in P articipants with 
Neovascular (Wet) Age- related Macular Degeneration  (wAMD) 
Protocol Number:  KS301P10 7 
Version Date:  16 Mar ch 2022  
Amendment Number:  2.0 
Supersedes:  Version 1. 1 (Dated: 13 May 2021 ) 
Test Product : KSI-301 
Brief Title:  A Study to Evaluate the Efficacy and Safety of KSI -301 
Compared to Aflibercept in P articipants with Neovascular (Wet) 
Age-related Macular Degeneration (wAMD)  
Study Phase:  3 
Study Acronym/Name:  DAYLIGHT  
Sponsor:  Kodiak Sciences Inc.  
2631 Hanover Street 
Palo Alto, CA 94304 USA 
Sponsor Contact & Medical 
Monitor:  
 
Kodiak Sc
iences Inc. 
IND Number:  136167  
Eudra CT Number:  2021 -000225 -27 
 
CONFIDENTIAL 
The information in this document is confidential and may not be disclosed to others in whole or in part without 
express, written authorization from Kodiak Sciences Inc., except to the extent necessary to obtain informed 
consent from persons receiving the investigational drug or their legal guardians, or for discussions with local 
regulatory authorities, institutional review boards (IRB), or persons participating in the conduct of the trial. 
 
FOR MEDICAL EMERGENCIES CONTACT:  
 
 
 
 
 
 

CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
2 PROTOCOL APPROV AL – SPONSOR SIGNATORY  
 
Study Title:   A Prospective, Randomized, Double- masked, Active Comparator -controlled, 
Multi -center, Two -arm, Phase 3 Study to Evaluate the Efficacy and Safety of 
Intravitreal KSI -301 Compared with Intravitreal Aflibercept in Participants with 
Neovascular (Wet) Age -related Macular Degeneration (wAMD) (DAYLIGHT ) 
Protocol Number:   KS301P107 
Version Date:  16 March 2022 
 
Protocol accepted and approved by: 
 
 
Kodiak
 Sciences Inc.  
2631 Hanover Street 
Palo Alto, CA 94304  
   
Signature   Date  
 
  

CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
3 PROTOCOL APPROV AL – PRINCIPAL INVESTIGATOR 
SIGNATORY  
 
Study Title:   A Prospective, Randomized, Double- masked, Active Comparator -controlled, 
Multi -center, Two -arm, Phase 3 Study to Evaluate the Efficacy and Safety of 
Intravitreal KSI -301 Compared with Intravitreal Aflibercept in Participants with 
Neovascular (Wet) Age -related Macular Degeneration (wAMD) (DAYLIGHT ) 
Protocol Number:   KS301P107 
Version Date:   16 March 2022 
 I have read the protocol described above. I agree to conduct the study as described in the 
protocol. I also agree to conduct this study in compliance with Good Clinical Practice (GCP) and all applicable national and local laws and regulations, as well as w ith the requirements of the 
appropriate Institutional Review Board or independent Ethics Committee (IRB/IEC) and any other institutional requirements. These are stated in “Guidance for Good Clinical Practice” International Council for Harmonisation (ICH) guideline E6(R1) of Technical Requirements for Registration of Pharmaceuticals for Human Use, the Declaration of Helsinki, and any other applicable regulatory requirements. No changes will be made to the study protocol without prior written approval of the Sponsor and the IRB/IEC. 
 Principal Investigator:  
  
Print Name of Investigator 
   
Signature  Date  
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
4 TABLE OF CONTENTS  
1.0 PROTOCOL SUMMARY ..............................................................................................12 
1.1 Synopsis .................................................................................................................12 
1.2 Schema  ...................................................................................................................17 
1.3 Schedule of Activities (SoA) .................................................................................18 
2.0 INTRODUCTION............................................................................................................20 
2.1 Study Rationale ......................................................................................................20 
2.2 Background ............................................................................................................20 
2.2.1 Neovascular (Wet) Age- related Macular Degeneration  ........................20 
2.2.2 Vascular Endothelial Growth Factor  .....................................................21 
2.2.3 Description of KSI-301 .........................................................................21 
2.3 Benefit/Risk Assessment  .......................................................................................22 
2.3.1 Known Potential Benefits .....................................................................22 
2.3.2 Known Potential Risks ..........................................................................22 
2.3.3 Overall Benefit/Risk Conclusion  ..........................................................25 
3.0 OBJECTIVES AND ENDPOINTS  ................................................................................26 
4.0 STUDY DESIGN  ..............................................................................................................27 
4.1 Overall Design  .......................................................................................................27 
4.1.1 Screening Period  ...................................................................................27 
4.1.2 Treatment Period  ...................................................................................28 
4.1.3 Administration of Study Intervention ...................................................28 
4.2 Scientific Rationale for Study Design ....................................................................29 
4.2.1 Choice of Population .............................................................................29 
4.2.2 Choice of Active Comparator Control ..................................................29 
4.2.3 Choice of Primary Endpoint and Analysis ............................................29 
4.2.4 Choice of Duration of Treatment and Follow-up ..................................30 
4.3 Justification for Dose .............................................................................................30 
4.3.1 KSI-301 Dose Rationale .......................................................................30 
4.3.2 Aflibercept Dose Rationale  ...................................................................31 
4.3.3 Sham Injection Rationale  ......................................................................31 
4.4 End of T
reatment ...................................................................................................31 
4.5 End of Study Definition .........................................................................................31 
4.6 Treatment After End of Study................................................................................31 
5.0 STUDY POPULATION ..................................................................................................32 
5.1 Inclusion Criteria  ...................................................................................................32 
5.1.1 Ocular Inclusion Criteria  .......................................................................32 
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
5 5.1.2 General Inclusion Criteria .....................................................................33 
5.2 Exclusion Criteria  ..................................................................................................34 
5.2.1 Ocular Exclusion Criteria  ......................................................................34 
5.2.2 General Exclusion Criteria  ....................................................................35 
5.3 Lifestyle Considerations ........................................................................................35 
5.4 Screen Failures  .......................................................................................................36 
5.5 Criteria for Temporarily Delaying Enrollment  ......................................................36 
6.0 STUDY INTERVENTION(S) AND CONCOMITANT THERAPY ..........................38 
6.1 Study Intervention(s) Administered .......................................................................38 
6.2 Preparation/Handling/Storage/Accountability .......................................................39 
6.2.1 Preparation, Handling, and Storage ......................................................39 
6.2.2 Study Intervention Accountability and Reconciliation .........................40 
6.3 Measures to Minimize Bias: Randomization and Masking ...................................41 6.3.1 Randomization ......................................................................................41 
6.3.2 Masking and Unmasking ......................................................................41 
6.4 Study Intervention Compliance .............................................................................42 
6.5 Dose Modification .................................................................................................43 
6.6 Continued Access to Study Intervention after the End of the Study .....................43 
6.7 Treatment of Overdose  ..........................................................................................43 
6.8 Concomitant Therapy.............................................................................................43 6.8.1 Prohibited Therapy ................................................................................44 
6.8.2 Supportive Care for Adverse Events .....................................................45 
7.0 DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  ......................................................................46 
7.1 Discontinuation of Study Intervention ...................................................................46 
7.1.1 Treatment Interruption and/or Discontinuation due to Adverse 
Events or Concomitant Procedures .......................................................46 
7.2 Participant Discontinuation/Withdrawal from the Study  .......................................47 
7.3 Lost to Follow-up ...................................................................................................48 
8.0 STUDY ASSESSMENTS AND PROCEDURES  ..........................................................49 
8.1 Efficacy Assessments .............................................................................................49 
8.1.1 Medical History and Demographic Data...............................................49 
8.1.2 Ophthalmic Exams  ................................................................................49 
8.1.3 Injec
tion Procedure ...............................................................................50 
8.1.4 Post-injection Assessments in the Study Eye .......................................50 
8.1.5 Best Corrected Visual Acuity (BCVA)  
 .................................................................................................51 

CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
6 8.1.6 Fundus Photography (FP) .....................................................................51 
8.1.7 Spectral Domain Optical Coherence Tomography (SD- OCT)  .............51 
8.1.8 Fluorescein Angiography (FA) .............................................................51 
8.2 Safety Assessments  ................................................................................................52 
8.2.1 Vital Signs  .............................................................................................52 
8.2.2 Clinical Safety Laboratory Assessments  ...............................................52 
8.2.3 Pregnancy Testing .................................................................................52 
8.3 Adverse Events, Serious Adverse Events, and Other Safety Reporting ................53 
8.3.1 Time Period and Frequency for Collecting AE and SAE 
Information  ............................................................................................53 
8.3.2 Method of Detecting AEs and SAEs .....................................................53 
8.3.3 Follow-up of AEs and SAEs .................................................................54 
8.3.4 Regulatory Reporting Requirements for SAEs .....................................54 
8.3.5 Pregnancy  ..............................................................................................54 
8.3.6 Adverse Events of Special Interest  .......................................................55 
8.4 Pharmacokinetics  ...................................................................................................56 
8.5 Genetics and/or Pharmacogenomics ......................................................................56 
8.6 Biomarkers  .............................................................................................................56 
8.7 Immunogenicity Assessments ................................................................................56 
8.8 Health Economics or Medical Resource Utilization and Health Economics  ........57 
9.0 STATISTICAL CONSIDERATIONS  ...........................................................................58 
9.1 Study Hypothesis ...................................................................................................58 
9.2 Sample Size Determination ....................................................................................58 
9.3 Analysis Sets  ..........................................................................................................59 
9.4 Statistical Analyses  ................................................................................................59 
9.4.1 General Considerations .........................................................................59 
9.4.2 Primary Endpoint(s) ..............................................................................60 
9.4.3 Secondary Endpoint(s) ..........................................................................61 
9.4.4 Tertiary/Exploratory Endpoint(s) ..........................................................62 
9.4.5 Safety Analysis  .....................................................................................62 
9.4.6 Pharmacokinetic and Biomarker Analysis  ............................................62 
9.5 Inte
rim Analysis  .....................................................................................................62 
10.0 APPENDICES WITH SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  ........................................................................63 
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ................64 
10.1.1 Regulatory and Ethical Considerations .................................................64 
10.1.2 Financial Disclosure and Financial Obligations ...................................64 
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
7 10.1.3 Informed Consent Process ....................................................................65 
10.1.4 Data Protection  ......................................................................................65 
10.1.5 Committees Structure  ............................................................................66 
10.1.6 Data Quality Assurance .........................................................................66 
10.1.7 Source Documents ................................................................................67 
10.1.8 Study and Site Start and Closure ...........................................................67 
10.1.9 Publication Policy  .................................................................................68 
10.2 Appendix 2: Clinical Laboratory Tests ..................................................................69 
10.3 Appendix 3: AEs and SAEs: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting ...................................................................70 
10.3.1 Definition of AE ....................................................................................70 
10.3.2 Definition of SAE .................................................................................71 
10.3.3 The Recording and Follow-Up of AE and/or SAE ...............................72 
10.3.4 Reporting of SAEs ................................................................................74 
10.4 Appendix 4: Grading Scale for Assessment of Anterior Chamber Flare or 
Cells, Vitreous Cells or Haze.  ................................................................................75 
10.4.1 Grading Scales for Anterior Chamber Cells or Flare ............................75 
10.4.2 Grading Scale for Vitreous Cells  ..........................................................76 
10.4.3 Grading Scale for Vitreous Haze  ..........................................................76 
10.5 Appendix 5: Unscheduled Safety Assessment Visits ............................................77 
10.6 Appendix 6: Contraceptive and Barrier Guidance .................................................78 
10.6.1 Definitions  .............................................................................................78 
10.6.2 Contraception Guidance ........................................................................79 
10.6.3 Collection of Pregnancy Information ....................................................79 
10.7 Appendix 7: Liver Safety .......................................................................................81 
10.8 Appendix 8: Protocol Amendment History ...........................................................82 
11.0 REFERENCES  .................................................................................................................83 
 
LIST OF TABLES  
Table 1:  Protocol KS301P107: Risk Assessment ....................................................23 
Table 2:  Protocol KS301P107: Study Interventions ................................................39 
Table 3:  Protocol KS301P107: Treatment Interruption Criteria ..............................47 
Table 4:  Protocol KS301P107: Required Safety Laboratory Tests .........................69 
Table 5:  Protocol KS301P107: Amendment History ...............................................82 
 
 
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
8 LIST OF FIGURES  
Figure 1:  Protocol KS301P107: Schema ...................................................................17 
Figure 2:  Protocol KS301P107: Masked Dosing Regimens by Week ......................28 
 
  
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
9 LIST OF ABBREVIATIONS 
Abbreviation  Definition  
ADA  Anti-drug antibody  
AE Adverse event  
AESI  Adverse event of special interest  
ALT  Alanine aminotransferase  
AMD  Age-related macular degeneration  
ANCOVA  Analysis of covariance  
AR Adverse reaction  
AST  Aspartate aminotransferase  
ATE  Arterial thromboembolic events  
AUC  Area under the curve (total exposure)  
BCVA  Best corrected visual acuity  
BP Blood pressure  
BUN  Blood urea nitrogen  
CFR  Code of federal regulations  
Cmax Maximum concentration observed  
CNV  Choroidal neovascularization  
COVID -19 Coronavirus -19 
CRO  Contract research organization  
CSR  Clinical study report  
CST Central subfield thickness  
DME  Diabetic macular edema  
DR Diabetic retinopathy  
DVD  Digital Video Disc  
EC Ethics committee  
ECG  Electrocardiograph  
eCRF  Electronic case report form  
EDC  Electronic data capture  
ET Early termination  
ETDRS  Early treatment diabetic retinopathy study  
EU European Union  
FA Fundus fluorescein angiography  
FAS Full-analysis set  
FDA  Food and Drug Administration  
FP Fundus photography  
GCP  Good clinical practice  
GGT  Gamma -glutamyl -transferase  
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
10 Abbreviation  Definition  
GLP  Good laboratory practice  
IB Investigator’s  Brochure  
ICF Informed consent form  
ICH International conference on harmonization  
ICMJE  International committee of medical journal editors  
IDMC  Independent Data Monitoring Committee  
IMP Investigational medicinal product  
IND Investigational new drug (application)  
IOP Intraocular pressure  
IP Investigational product  
IRB Institutional review board  
IEC Independent or institutional ethics committee  
IRC Intraretinal cysts  
IRF Intraretinal fluid  
ITT Intent to treat  
IRT 
IUD Interactive Response Technology  
Intrauterine device  
IUS Intrauterine hormone -releasing system  
IVT Intravitreal  
  
LPLO  Last participant,  last observation  
ME Macular edema  
MedDRA  The medical dictionary for regulatory activities  
NAB  Neutralizing antibody  
NOAEL  No observed adverse effect level  
OCT  Optical coherence tomography  
OU Both eyes  
PI Principal Investigator  
PK Pharmacokinetic  
Q8W  Every eight weeks  
RPE Retinal pigment epithelium  
RVO  Retinal vein occlusion   
SAE  Serious adverse event  
SAP Statistical analysis plan  
SAR  Serious adverse reaction  
SAR -CoV -2 Severe acute respiratory syndrome coronavirus 2  
SD-OCT  Spectral domain optical coherence tomography  

CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
11 Abbreviation  Definition  
SDV  Source data verification  
SE Study Eye 
SGOT  Serum glutamic oxaloacetic transaminase  
SGPT  Serum glutamic pyruvic transaminase  
SoA Schedule of activities  
SRF Subretinal  fluid  
SUN  Standardization of uveitis nomenclature  
SUSAR  Suspected unexpected serious adverse reactions  
TEAEs  Treatment emergent adverse events  
ULN  Upper limits of normal  
VA Visual acuity  
VEGF  Vascular endothelial growth factor  
wAMD  Wet (neovascular) age-related macular degeneration  
WBC  White blood cell  
WHODrug  World health organization drug dictionary  
WOCBP  Women of childbearing potential  
 
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
12 1.0 PROTOCOL SUMMARY 
1.1 Synopsis  
Protocol Number: KS301P107  Version : 2.0 For National Authority Use 
Only  
 IND Number: 136167  EudraCT Number: 2021 -000225 -27 
Sponsor:  
Kodiak Sciences Inc.  
2631 Hanover Street  
Palo Alto, CA  94304 (USA)  
Investigational Product : 
KSI-301 
Title of Study:  
A Prospective, Randomized, Double -masked, Active Comparator -controlled, Multi- center, Two -arm, Phase 3 
Study to Evaluate the Efficacy and Safety of Intravitreal KSI -301 Compared with Intravitreal Aflibercept in 
Participants with Neovascular (Wet) Age- related Macular Degeneration (wAMD) ( DAYLIGHT ) 
Brief Title:  
A Study to Evaluate the Efficacy and Safety of KSI- 301 Compared to Aflibercept in Participants with Neovascular 
(Wet) Age-related Macular Degeneration (wAMD)  
Brief Study Rationale:  
KSI-301 is a novel , potent, long -acting  biopharmaceutical that inhibits v ascular endothelial growth factor ( VEGF ). 
KSI-301 has  enhanced retinal bioavailability , a greater inhibitory potency, and an extended ocular half -life, which 
may result in improved efficacy  and/or a less frequent treatment regimen.  Intensive treatment with aflibercept has 
been shown to provide better visual acuity results in a subset of patients with persistent fluid in the retina. Given 
the enhanced properties of KSI -301, this study has been designed to evaluate an intensive  treatment regimen of 
KSI-301 5  mg compared to aflibercept 2 mg in participants with wAMD.   
Development Phase:  3 Countries /Regions: NA (North America)  and EMEA  (Europe, 
Middle -East, Africa)  
Study Period: Approximately  2 years  
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
15 Protocol Number: KS301P107  Version : 2.0 For National Authority Use 
Only  
 IND Number: 136167  EudraCT Number: 2021 -000225 -27 
Sponsor:  
Kodiak Sciences Inc.  
2631 Hanover Street  
Palo Alto, CA  94304 (USA)  
Investigational Product : 
KSI-301 
Title of Study:  
A Prospective, Randomized, Double -masked, Active Comparator -controlled, Multi- center, Two -arm, Phase 3 
Study to Evaluate the Efficacy and Safety of Intravitreal KSI -301 Compared with Intravitreal Aflibercept in 
Participants with Neovascular (Wet) Age- related Macular Degeneration (wAMD) ( DAYLIGHT ) 
Study Intervention (Active Control /Investigational Medicinal Product) , Dose , and Route  of Administration:  
Treatment Group  B: 
• Day 1 to Week 12 : aflibercept 2  mg once every 4 weeks for 3 monthly doses via intravitreal injection , 
followed by a sham injection at week 12; and  
• Week  16 to Week 44 : aflibercept 2 mg once every 8 weeks  via intravitreal injection . Sham injections will be 
administered at e ach monthly visit if an active treatment is not administered . 
Efficacy  Evaluation : 
Unless stated otherwise, all efficacy analyses will be performed on the intent to treat (ITT) population. The primary 
endpoint is mean change in ETDRS BCVA from Day 1 to the average  of Week s 40, 44, and 48 . The primary 
assessment of efficacy will be based on a pairwise comparison in mean  change in BCVA between treatment group 
A (KSI -301 5 mg) and treatment group B (aflibercept 2  mg). Other efficacy outcomes will be evaluated using 
ophthalmic assessments  (including tonometry), fundus photography, s pectral domain (SD )-OCT , and f luorescein 
angiography (FA ). Secondary endpoints for efficacy will be assessed  at Week 48. Planned time points for all 
efficacy  assessments are provided in the Schedule of Activities ( SoA) (Section 1.3 ). 
Safety  Evaluation : 
After informed consent has been obtained but prior to initiation of study intervention, only serious adverse events 
(SAEs) caused by a protocol -mandated intervention should be reported. After initiation of study intervention (Day 
1), all AE  and SAE information  will be collected  until the final safety follow -up visit at Week 52 or the ET visit, if 
applicable , as specif ied in Section 1.3 . The safety analysis will use  outcomes of all participants who were exposed 
to study treatment , regardless of adherence to the protocol or treatment outcome.  All reported adverse events 
(ocular and otherwise) in the safety population will be listed by MedDRA term, frequency, severity, association to 
the study therapy, and treatment group. By- treatment incidence rates will also be calculated for the treatment 
groups. For certain adverse events, per -injection rates will also be described . 
Pharmacokinetic/Biomarker Evaluation:  
Plasma concentration s of study intervention (KSI -301) will be measured , as specified in the SoA ( Section 1.3 ). 
Blood samples will also be analyzed for anti -drug ant i bodies  (ADAs) . For exploratory purposes,  
  

CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
16 Protocol Number: KS301P107  Version : 2.0 For National Authority Use 
Only  
 IND Number: 136167  EudraCT Number: 2021 -000225 -27 
Sponsor:  
Kodiak Sciences Inc.  
2631 Hanover Street  
Palo Alto, CA  94304 (USA)  
Investigational Product : 
KSI-301 
Title of Study:  
A Prospective, Randomized, Double -masked, Active Comparator -controlled, Multi- center, Two -arm, Phase 3 
Study to Evaluate the Efficacy and Safety of Intravitreal KSI -301 Compared with Intravitreal Aflibercept in 
Participants with Neovascular (Wet) Age- related Macular Degeneration (wAMD) ( DAYLIGHT ) 
Statistical Methods:  
The study hypothesis is that t reatment with KSI -301 5 mg will provide a non -inferior mean change in BCVA to 
aflibercept 2  mg in participants with wAMD. Using ETDRS BCVA data collected up to Week 48, the treatment 
groups  will be compared using a non- infer iority analysis, with a margin . Confidence intervals  
(CI) will be 100(1- 2 α) or 95%  CI. 
The sample size of  approximately 500 (250 per group) participants was calculated using t he following 
assumptions:  
• Overall type I error rate of 0.025. Testing at the 0.025 level for non- inferiority corresponds to setting 95% CIs. 
• Statistical power of ≥90%.  
• Standard deviation of the distribution of change in visual acuity from baseline of  letter s . 
• The maximum , clinically acceptable true difference for KSI- 301 to be considered non- inferior, or the “non-
inferiority margin ”, .  
• The s ta
tistical test used to compare the two treatment groups  at Week 48 is an independent t -test on the mean 
change in visual acuity from baseline.  
• Lost to follow -up/dr opout rate of approximately . 
Analysis of study data will be performed when all participants have either completed the Week 48 visit or have 
discontinued from the study, all data have been entered into the database, cleaned and verified as appropriate, and 
the database has been locked.  
Data Monitoring:  
An Independent Data Monitoring Committee (IDMC) will monitor the study conduct and participant safety on an ongoing basis.  
Date of Protocol /Amendment : 16 Mar ch 2022  
 
 

CONFIDENTIAL   Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
17 1.2 Schema  
Figure 1: Protocol KS301P107: Schema  
 
Abbreviations: Q4W = once every four (4) weeks; Q8W = once every eight (8) weeks.  
  

CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
20 2.0 INTRODUCTION 
KSI-301 is a novel, potent, long- acting  biopharmaceutical that inhibits vascular endothelial 
growth factor ( VEGF ). It is being developed to treat neovascular ( wet) age-related macular 
degeneration ( wAMD ), as well as macular edema (ME) secondary to retinal vein occlusion 
(RVO) , diabetic macular edema ( DME), and diabetic retinopathy (DR) . KSI -301 offers the 
potential for participants to experience a longer interval between consecutive intravitreal 
injections  compared to existing anti- VEGF therapies.  Thus, KSI -301 may have the potential to 
improve real -world outcomes of anti- VEGF therapy , which in patients with wAMD, is  currently 
limited  by both the high treatment burden and insufficient durability of effect .  
2.1 Study Rationale 
Although substantial visual acuity benefits have been demonstrated with the approved intravitreal VEGF inhibitors (e.g., aflibercept and  ranibizumab ) in the first -line treatment of 
wAMD, some patients have an  insufficient response to treatment, with continued loss of visual 
acuity  and/or persistent retinal fluid  (Brown 2006; Heier 2012; Rosenfeld 2006). 
Pharmacokinetic modeling suggests that more frequent dosing with anti-VEGF therapy could be beneficial for such patients  (Stewart 2012), and intensive treatment with aflibercept has shown to 
provide better visual acuity results in a subset of patients with persistent fluid in the retina ( Jaffe 
2016). With  enhanced retinal bioavailability , a greater inhibitory potency, and an extended  
ocular half -life (Section 2.2.3), KSI -301 may lead to  improved treatment outcomes . The ongoing 
Phase 2b/3 Study of KSI -301 versus  aflibercept in participant s with wAMD , Study KSI- CL-102, 
evaluates  dosing regimens of KSI-301 at intervals of every 12 weeks or longer. Thus, this study, 
Study KS301P107, has been  designed to evaluate an intensive treatment regimen of KSI -301 5 
mg (Q4W) compared to aflibercept 2  mg (Q8W after 3 monthly loading doses) in participants 
with wAMD.   
2.2 Background 
2.2.1 Neovascular (Wet) Age -related Macular Degeneration   
Age-related macular degeneration (AMD)  is a progressive disease that affect s the macula, which 
is the central portion of the retina and is the region of the eye responsible for sharp, central vision and color perception. AMD affects people 50 years of age and older and the likelihood of AMD progression and associated vision loss increases with age. Population-based studies have shown that AMD accounts for 8.7% of all blindness worldwide and is the most common cause of blindness in developed countries. ( Wong 2014) 
Neovascular (wet) AMD (wAMD) is an advanced form of AMD that is  characterized by 
choroidal neovascularization and fluid leakage within and under the retina. I n the United States 
and the European Union (EU), wAMD is the leading cause of severe vision loss in people over the age of 50. I n the United States , the prevalence of wAMD is approximately 1.25 million, with 
an annual incidence of approximately 148,000 new cases ( Wong 2014). Like AMD, t he 
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
21 likelihood of disease progression of wAMD increases with age, and both the prevalence and 
incidence of wAMD are  projected to accelerate worldwide.   
Approximately 50% of patients  presenting with wAMD in one eye will develop wAMD in the 
fellow  eye within five years, leading to a substantial number of patients  requiring treatment in 
both eyes ( Chew 2014). In many eyes with wAMD, the disease can progress quickly, with rapid 
loss of central vision needed for activities such as reading and driving. Untreated or undertreated wAMD can result in subretinal scarring with irreversible photoreceptor damage and loss, and ultimately  permanent vision impairment or blindness. 
2.2.2 Vascular Endothelial Growth Factor  
VEGF stimulates vascular endothelial cell growth and induces vascular permeability. These biologic activities give it a central role in angiogenesis, both in normal and pathologic conditions. VEGF plays a critical role in the pathophysiology of choroidal and retinal neovascular diseases such as wAMD ; DR, including DME; and ME due to RVO ( Rubio 2016). 
Inhibition of pathologic VEGF activity is both an “anti-angiogenic” and “anti- permeability ” 
approach to treat choroidal and retinal neovascular diseases and has been shown to be effective in preserving and improving visual acuity ( Campochiaro 2015b; Cheung 2010). 
Among the VEGF isoforms, VEGF- A is the most strongly linked to angiogenesis and vascular 
leakage ( Campochiaro 2015a ). Intravitreal VEGF -A inhibitors such as aflibercept and 
ranibizumab have been approved by regulatory authorities worldwide for use in these retinal  
vascular diseases. Phase 3 clinical trials of ranibizumab demonstrated that monthly injections of 
ranibizumab for DME and wAMD resulted in substantial visual acuity gains ( Brown 2006; 
Nguyen 2012; Rosenfeld 2006). Similarly, the Phase  3 clinical trials of aflibercept in patients 
with wAMD demonstrated that every 8-week (Q8W) dosing of aflibercept (after 3 once-monthly loading doses) was non-inferior to monthly ranibizumab ( Heier 2012). 
The anti -VEGF  therapy is  well -established  for the  treatment of wAMD ( Schmidt-Erfurth 2014). 
However,  some patients have an  insufficient response to treatment , with continued loss of BCVA 
and/or persistent retinal fluid  using the approved posologies  (Brown 2006; Heier 2012; 
Rosenfeld 2006). Pharmacokinetic modeling suggests that more frequent dosing with anti- VEGF 
therapy could be beneficial for such patients ( Stewart 2012), and intensive treatment with 
aflibercept has shown to provide better visual acuity results in a subset of patients with persistent fluid in the retina ( Jaffe 2016 ). 
2.2.3 Description of KSI -301 
KSI-301 is an antibody biopolymer conjugate (ABC) developed using the Sponsor’s proprietary  
ABC Platform ™ technology. The antibody portion of KSI-301 binds to VEGF-A with high 
affinity and inhibits the ability of VEGF -A to bind and activate its cognate receptors (VEGFR1 
and VEGFR2), thereby acting as an anti -angiogenic and anti- permeability  agent . The inert 
biopolymer portion is an ultra -hydrophilic phosphorylcholine polymer that significantly 
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
22 increases the overall molecular size of KSI -301, which in turn extends its ocular half- life by a 
factor  and ocu lar concentrations at three months by a factor of  compared to 
aflibercept . Due to the biophysical and biological properties of the ABC P latform  on which it is 
built, KSI -301 is designed to have improved ocular durability, bioavailability, biocompatibility , 
and stability, and rapid systemic clearance. These  properties make KSI -301 an ideal candidate 
for the management of retinal vascular diseases.  
A detailed description of the chemistry, pharmacology, efficacy, and safety of KSI -301 is 
provided in the Investigator’s Brochure (IB). 
2.3 Benefit/Risk Assessment  
Detailed information about the known and expected benefits and risks and reasonably expected  
adverse events of  KSI-301 may be found in the IB. A brief overview of known potential benefits 
and risks is provided in the subsections that follow. 
2.3.1 Known Potential Benefit s 
KSI-301, an intravitreal VEGF inhibitor  developed to treat wAMD, benefits from a well -
documented mechanism  of action in retinal vascular disease (Homayouni 2009). The efficacy 
and safety of commercially  available intravitreal VEGF inhibitors in wAMD is also well -
documented and established ( Schmidt-Erfurth 2014). Based on its molecular design and 
structure, in vitro  and in vivo  nonclinical testing, and clinical data to date, it is expected that the 
efficacy and safety of KSI -301 should be at least comparable to standard of care. 
The use of anti -VEGF  therapy is a well -established  treatment for wAMD ( Schmidt- Erfurth 
2014). However,  some patients have an insufficient response to treatment, with continued loss of 
BCVA and/or persistent retinal fluid using the approved posologies  (Brown 2006; Heier 2012; 
Rosenfeld 2006). Pharmacokinetic modeling suggests that more frequent dosing with anti- VEGF 
therapy could be beneficial for such patients ( Stewart 2012), and intensive treatment with 
aflibercept has been shown to provide better visual acuity results in a subset of patients with 
persistent fluid in the retina ( Jaffe 2016). Thus, an intensive treatment regimen of KSI -301 may 
provide clinically relevant benefits over existing therapies for pati ents with wAMD. 
2.3.2 Known Potential Risk s 
Potential risks of treatment with KSI -301 were identified based on therapeutic protein class 
effects, VEGF -inhibition class effects, the intravitreal route of administration, nonclinical 
findings, and Phase 1 /1b clinical experience. In consideration of the Coronavirus disease 
(COVID -19) pandemic caused by the virus SARS-CoV-2 and the impact it may have on clinical 
trials, COVID -19 related risks to participants are also carefully considered . A summary of 
known potential risks associated with KSI-301 is provided in Table 1 . Risks associated with 
COVID-19 are discussed below in Section 2.3.2.1. 
  

CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
23 Table 1:  Protocol KS301P107: Risk Assessment  
Potential Risk 
of Clinical 
Significance  Summary of Data/ Rationale for Risk  Mitigation Strategy  
Study Intervention [KSI- 301] 
Immunogenicity  As with all therapeutic proteins, there is 
a potential for an immune response in participants treated with KSI -301. 
Clinical experience with commercially 
available intravitreal VEGF inhibitors has shown that SAEs related to inflammatory reactions can occur .  
Additional details are provided in IB Section 5.4.2.1. Participants will be monitored following the injection and instructed to report any symptoms suggestive of an immune response  without delay 
to facilitate early diagnosis and treatment (Section  8.1.4). 
Participants with known hypersensitivity to intravitreal agents such as aflibercept or any 
ingredient of KSI -301 are excluded from this study 
(Section 5.2.2).  
Arterial 
thromboembolic 
events  (ATEs) ATEs are defined as nonfatal stroke, 
nonfatal myocardial infarction, or 
vascular death (including deaths of 
unknown cause). There is a potential 
risk of ATEs following intravitreal use of VEGF inhibitors.  
Additional details are provided in IB Section 5.4.2.2. Participants with recent history  (6 months)  of 
myocardial infarction, stroke, transient  ischemic 
attack, acute congestive heart failure or any acute 
coronary event are excluded from this study 
(Section 5.2.2). 
Intraocular inflammation  Intraocular inflammation has been reported following treatment with intravitreal anti- VEGF medicines, 
including KSI-301.  
Additional details are provided in IB Section 5.4. 2.3. Participants will be monitored following the injection and instructed to report any symptoms suggestive of intraocular inflammation without delay to facilitate early diagnosis and treatment  
(Section 8.1.4). Participants with active or 
suspected ocular infection or inflammation in 
either eye (e.g., blepharitis, infectious conjunctivitis, keratitis, scleritis, endophthalmitis) are excluded from this study ( Section 5.2.1).  
Participants with active  intraocular inflammation 
will have study treatment interrupted 
(Section  7.1.1). 
Hypersensitivity  Hypersensitivity reactions may manifest as rash, pruritus, urticaria, severe anaphylactic/ anaphylactoid reactions, or 
severe intraocular inflammation .  
Additional details are provided in IB Section 5.4.2. 4. Participants with known hypersensitivity to intravitreal agents such as aflibercept or any ingredient of KSI -301 are excluded from this study 
(Section 5.2.2). 
 
  
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
24 Table 1:  Protocol KS301P107: Risk Assessment  (Cont’d) 
Potential Risk 
of Clinical 
Significance  Summary of Data/ Rationale for Risk  Mitigation Strategy  
Study Procedures  
Risks associated 
with the method of administration  These risks include e ndophthalmitis , 
increases in intraocular pressure, retinal detachment, retinal tear, traumatic 
cataract, and  intraocular he morrhage . 
Additional d etails are provided in 
IB Section 5.4.2. 5. Proper and aseptic injection technique when 
administering intravitreal injections will be used  
(Section 8.1.3). Participants will be monitored 
following the injection and instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay to facilitate early diagnosis and treatment  (Section 8.1.4) . 
Intraocular pressure and the perfusion of the optic nerve head will also be monitored and managed 
(Section 8.1.4) . Participants with active ocular 
infection or inflammation in either eye (e.g., blepharitis, infectious conjunctivitis, keratitis, scleritis, endophthalmitis) are excluded from this 
study ( Section 5.2.1 ). 
Exposure to 
SARS -CoV -2 
virus  Section 2.3.2.1  Section 2.3.2.1  
Abbreviations : ATEs = Arterial thromboembolic events ; IB = Investigator ’s Brochure; SAE = serious adverse event; 
VEGF = vascular endothelial growth factor.  
 
2.3.2.1 Risks A ssociated with E xposure to  the V irus SARS -CoV-2 
In consideration of the Coronavirus disease ( COVID -19) pandemic caused by the virus 
SARS -CoV-2 and the impact it may have on clinical trials, COVID -19 related risk s to 
participants are carefully considered  and will be documented on an ongoing basis. Because 
wAMD is an acute onset, rapidly progressing disease, early diagnosis and treatment with 
intravitreal anti- VEGF therapy  is associated with better functional outcomes, including 
prevention of irreversible vision loss ( Schmidt-Erfurth 2014). Moreover, intravitreal anti- VEGF 
treatment is recognized as an essential health  care service during the pandemic by 
ophthalmology physician societies worldwide. This trial affords all participants the opportunity to receive anti-VEGF therapy for their wAMD. M easures  that prioritiz e trial participant safety 
and data integrity  have been developed in consideration of local guidelines.  
In order to minimize  any added risk of exposure associated with trial participation beyond that 
associated with standard  of care treatment,  the Schedule of Activities  (SoA) (Section 1.3) has 
been optimized to allow for an adequate follow -up and assessment of the safety and efficacy of 
KSI-301 without unnecessarily increasing participant exposure beyond that which may already 
exist from their attendance at clinic visits for anti- VEGF treatment of their wAMD.  
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
25 As the pandemic situation develops, the Sponsor will reassess risks, which will be documented 
as part of the Sponsor's trial master file. In the event that escalation of the pandemic during this trial and local circumstances lead to a local change in risk assessment, additional measures may be implemented . In this case,  an Investigator- driven risk assessment will be conducted and 
documented in the Investigator’s site master file and communicated to the Sponsor. 
2.3.3 Overall Benefit /Risk Conclusion  
The potential benefits of treatment for wAMD with KSI -301 have been considered against both 
the risks associated with KSI-301 treatment and the COVID -19 pandemic. Participants in this 
study will be carefully monitored with special attention to known and  potential risks  and 
managed as appropriate. Exclusion criteria restrict enrollment of participants at higher risk, and 
routine monitoring and follow-up evaluations will be conducted for early detection of any AEs, as noted in Section 8.3. Reassessment of the risks will continue as the COVID -19 situation 
develops and any changes to this approach will be documented accordingly. 
Because wAMD is an acute onset, rapidly progressing disease, early diagnosis and treatment 
with intravitreal anti- VEGF therapy  is associated with better functional outcomes, including 
prevention of irreversible vision loss ( Schmidt-Erfurth 2014). Moreover, intravitreal anti- VEGF 
treatment is recognized as an essential health  care service during the pandemic by physician 
groups worldwide. Therefore , based upon the well -known, clinically demonstrated  mechanism of 
action  (Homayouni 2009 ); favorable nonclinical and Phase 1a/1b  safety, tolerability and 
bioactivity data ; and a study design that includes extensive monitoring and COVID-19 risk 
mitigation , the Sponsor considers that the potential risks of study participation are outweighed by 
the value of the information to be gained and further study is warranted. 
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
27 4.0 STUDY DESIGN  
4.1 Overall  Design  
This is a  Phase 3 , prospective, randomized, double-masked, two -arm, multi-center study 
evaluating the efficacy and safety of repeated intravitreal dosing of KSI -301 5 mg in participants  
with treatment -naïve wAMD. 
The overall duration of the study is approximately 52 weeks  after the last participant is 
randomized to the study. Participant duration is defined as the date a signed written informed 
consent is provided through the last safety follow- up visit at Week 52. Thus, participant duration 
is approximately 55 weeks  and includes a screening period of up to 21 days (D ays -21 to -1), a 
treatment period of approximately 44 weeks (Day 1 to Week 44), a 4 -week follow -up period for 
safety and efficacy assessments  at Week 48, and a final  follow- up for safety assessments  at 
Week 52   
The prim
ary endpoint is defined as the mean change in ETDRS BCVA from baseline (Day 1) to 
the average of Week s 40, 44, and 48.  
A single eye per participant will be designated as the Study Eye. If both eyes are eligible to 
become the Study Eye, the eye with worse BCVA at Screening will be selected as the Study Eye. If both eyes are eligible and have the same BCVA, the decision of which eye to select as the Study Eye will be made by the Investigator. 
Participants will be randomly assigned (1:1) into one of two  treatment groups: 
• KSI-301 5 mg , or 
• Aflibercept  2 mg . 
Randomization will be stratified by  
Additi onal details of 
the randomization methods are described in the statistical analysis plan (SAP).  
4.1.1 Screening  Period  
Participants will provide written informed consent to participate in the study before completing 
any protocol-specified procedures or evaluations not considered to be part of the participant’s standard care. After providing informed consent, participants will be evaluated for eligibility  
criteria during the screening period within 21 days before administration of study intervention(s).  
Participants who do not meet eligibility criteria within the 21 -day screening period will not be 
eligible for randomization and will be considered as screen -failed . However, a participant may 
be re -screened  up to  one additional time  at the discretion of the Investigator and in consultation 
with the Sponsor ( Section 5.4). Instructions for participants who meet all eligibility criteria at the 

CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
28 Screening visit but do not meet the BCVA and/or SD- OCT CST eligibility criteria when they 
return for the planned Day 1 visit are provided in Section 5.5. 
When re -screening  tests and procedures have been completed and results are available indicating 
the participant is eligible for study participation, the participant may be enrolled. When re-
screening  a participant,  a new screening/enrollment number will be generated by the IRT system 
to ensure that  there is an audit trail for the screen -failed participant .  
4.1.2 Treatment Period  
Participants in this study will be treated until Week 44 and will have an additional efficacy and/or safety follow -up at Week s 48 and 52, unless the Investigator decides to discontinue 
treatment, the Sponsor decides to terminate the study, or until any of the reasons for withdrawal /discontinuation provided in Section 7.2 are met.  
4.1.3 Administration of Study Intervention  
All participants will be treated starting on Day 1 through Week 36 according to their respective treatment group, as shown in Figure 2.  
Participants randomized to the KSI-301 treatment group will receive KSI -301 5 mg  
onc
e every four (4) weeks from Day 1 to Week 44.  
Participant s randomized to the aflibercept treatment group will initially  receive three (3) monthly 
doses of aflibercept 2 mg (50  µL) at Day 1, Week 4, and Week 8 , followed by aflibercept 2 mg 
(50 µL) once every 8 weeks (Q8W) until Week 44 . Participants randomized to the aflibercept 
treatment group will receive a sham injection at each visit that aflibercept is not administered 
(i.e., at Weeks 12, 20, 28, and 36).  
Figure 2: Protocol KS301P107: Masked Dosing Regimens by Week 
  
Abbreviations: PE = primary endpoint; Q4W = once every four (4) weeks; Q8W = once every eight (8) weeks; 
SA = safety assessment.  
 

CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
29 4.2 Scientific Rationale for Study Design  
This is a randomized, active comparator -controlled, double-masked, multi- center, Phase 3 study 
to evaluate the efficacy and safety of intravitreal KSI -301 compared with intravitreal aflibercept 
in participants with wAMD. A randomized, double-masked design minimizes  bias and is well-
established for demonstrating the safety and efficacy  of an investigational treatment. The 
rationale s for other key design features are provided below. 
4.2.1 Choice of Population 
KSI-301 is being evaluated as a first- line anti-VEGF medicinal product for the management of 
wAMD. Thus, participants must not  have had prior use of an approved or investigational 
treatment (e.g., anti- VEGF) for wAMD in the Study Eye.  
Enrollment of  participants who are treatment -naïve for wAMD helps to minimize biases inherent 
in the inclusion of participants who have failed prior lines of therapy. Treatment- naïve 
participants with best corrected visual acuity ( BCVA ) of 8 3 to 25 letters will be enrolled because 
they are expected to be broadly representative of the general population of patients treated with 
first-line anti-VEGF with diagnosis of wAMD.  
4.2.2 Choice of Active  Comparator Control 
An active comparator was selected for this trial because an effective treatment currently exists , 
rendering placebo (sham injection) control unethical.  
The use of VEGF -inhibition therapy is a well -established  treatment for wAMD ( Schmidt- Erfurth 
2014). Three highly potent anti -VEGF biologics are currently  approved by both the United States 
(US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA ) for the 
treatment of wAMD: ranibizumab (Lucentis®), brolucizumab (Beovu®), and aflibercept 
(Eylea®). Aflibercept is chosen as the active comparator for this trial because the majority of 
patients with wAMD treated in routine clinical practice with an approved anti- VEGF receive 
aflibercept.  
4.2.3 Choice of Primary  Endpoint  and Analysis 
The primary endpoint, me an change in BCVA, was selected based on health authority feedback 
and precedent for Phase 3 studies in wAMD. 
A non- inferiority  primary analysis  was selected because aflibercept  result s in significant clinical 
benefit for most patients, when administered  according to the approved posology. KSI -301 
efficacy outcomes are expected to be comparable (non- inferior) to  aflibercept , but with the 
potential for improved outcomes in some patients . Consequently, the a priori  assumption is that 
it is unlikely that KSI -301 (or any novel anti- VEGF) would demonstrate clinically meaningful 
superiority in vision outcomes to an approved anti -VEGF agent in a well -conducted, head -to-
head trial , for the overall population.  
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
30 A non- inferiority margin of  was selected based on health authority feedback. Five  letters 
represent  one line on the ETDRS visual acuity chart and is considered by many physicians to be 
a clinically  meaningful change. Therefore,   as a n upper threshold excludes the potential 
for clinically meaningful treatment effect differences between KSI-301 and aflibercept. 
4.2.4 Choice of Duration of T reatment  and Follow- up 
The duration of treatment in this study will be the same for both groups (i.e., KSI- 301 and 
aflibercept)  (i.e., 44 weeks) .  
The primary endpoint will be assessed using ETDRS data collected up to Week 4 8. This time  
point and associated duration of treatment was selected on the basis of health authority feedback 
and precedent for other ongoing Phase 3 trials in wAMD.  
The choice of  a safety follow-up interval of 8 weeks after the last dose is based on the expected 
duration of effect for KSI -301 and aflibercept.  
4.3 Justification for Dose 
4.3.1 KSI-301 Dose Rationale 
The durability and pharmacological effect  of intravitreal anti- VEGF therapy is proportional to 
the concentration , potency, and half-life of the drug. A KSI-301 5 mg dose has approximately 
times  the equivalent molar dose of anti-VEGF binding capacity, at the time of injection, 
rela
tive to 2  mg aflibercept . Preclinical model ing suggests that KSI-301 5 mg results in 
fold the equivalent ocular concentration of aflibercept 2 mg three months after dosing.  
Both KS
I-301 2.5 mg and KSI -301 5 mg that are being evaluated  in the ongoing Phase 1b 
portion of Study KSI -CL-101 have not resulted in any dose limiting ocular or systemic toxicities  
and, as expected,  have no clear dose-efficacy response relationship. Because the 5 mg dose of 
KSI-301 may have incrementally improved pharmacological effect s compared to the 2.5 mg 
dose, the 5 mg dose has been selected for this study.  The  injection volume used  to deli
 ver a 5 mg dose has been well-tolerated in previous 
KSI-301 studies (additional information can be found in the IB) as well as in other studies for of 
 
The overa
ll development objective of KSI -301 in the treatment of wAMD is to reduce the 
number of required intravitreal injections , and with it the treatment burden for patients, 
clinicians,  and health systems. However, establishing the safety and efficacy of an  intensive 
treatment approach with KSI-301 is of importance for and of potential benefit to patients who 
experience a limited or insufficient response to extended interval treatmen t. 

CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
31 4.3.2 Aflibercept Dose Rationale 
In the US, the recommended dose for aflibercept in wAMD is 2  mg (0.05 mL)  administered by 
intravitreal injection every 4 weeks (approximately every 28 days, monthly) for the first 12 
weeks (3 months), followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks (2 months).  
In the EU, the recommended  dose for aflibercept is 2  mg per month for three consecutive doses. 
The treatment interval is then extended to two months . The treatment interval may then be 
maintained at two months or further extended using a treat- and-extend dosing regimen, where 
injection intervals are increased in 2 - or 4 -weekly increments to maintain stable visual and/or 
anatomic outcomes.  
In the absence of a recommended posology that is consistent between regions, the Sponsor 
considers that a once every two -month (Q8W) interval after three initial loading doses provides 
the maximum possible treatment effect and best enables a head -to-head comparison with 
KSI-301 without undue risk. 
4.3.3 Sham Injection Rationale 
Sham injections are used to preserve study masking and minimize bias. Participants in the aflibercept treatment group will receive sham injections at each  monthly visit when an active 
treatment is not administered . 
4.4 End of Treatment  
Participant s may withdraw from the study at any time and for any reason without prejudice to 
their future medical care by the Investigator or at the study site. Every effort should be made to 
keep participant s in the study. The reasons for end-of- treatment/early termination are provided in 
Section 7.0. 
4.5 End of Study  Definition  
The end of the study is defined as the last follow- up visit of the last participant enrolled ( i.e., the 
last enrolled participant’s final  visit) or a Sponsor decision to terminate the study, whichever 
comes first . 
A participant is considered to have completed the study if he/she has completed all phases of the 
study, including the Week 52 safety follow- up assessment.  
4.6 Treatment After End of Study  
All participants will return to standard of care treatment, at the discretion of their T reating 
Physician, after complet ion of their final follow -up visit or once they discontinue from the study 
prematurely. The Sponsor will not provide continued access to study treatment following the end of the study or the end of each participant’s study treatment period. 
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
32 5.0 STUDY POPULATION 
Participants will be randomized to a specified treatment group only if they meet all the inclusion 
criteria and none of the exclusion criteria. 
Deviations from the inclusion and exclusion criteria are not allowed because they can potentially 
jeopardize the scientific integrity of the study, regulatory acceptability, or participant safety. Therefore, adherence to the criteria as specified in the pr otocol is essential. Prospective approval 
of protocol deviations to recruitment and enrollment criteria, also known as protocol waivers or exemptions, are not permitted.  
Inclusion/exclusion criteria ( Sections 5.1 and 5.2) will be assessed at Screening and on Day 1 to 
determine a participant’s eligibility for the study. Instructions for participant s who  meet all 
eligibility criteria at the Screening visit but do not meet the BCVA and/or SD- OCT CST 
eligibility criteria when they return for the planned Day 1 visit are provided in Section 5.5. 
5.1 Inclusion Criteria  
Participants are eligible to be included in the study only if all the criteria in Sections 5.1.1 and 
5.1.2 apply. 
5.1.1 Ocular Inclusion Criteria  
Where applicable inclusion criteria will be confirmed or assessed by the independent, masked 
image Reading Center.   
1. Active , treatment -naïve choroidal neovascularization (CNV) secondary to AMD, including 
subfoveal, juxtafoveal, and extrafoveal  lesions, or retinal angiomatous proliferations (RAP) 
lesions with a CNV component that affect s the central subfield , as evidenced by FA or OCT 
in the Study Eye at Screening.  
2. The CNV area in the Study Eye must be at least 50% of total lesion size  at Screening.  
3. The lesion area in the Study Eye must be <30 mm
2 (12-disc areas)  and can include any CNV 
lesion subtype. 
4. Intra - and/or subretinal fluid and/or subretinal hyperreflective material  (SHRM) affecting the 
central subfield of the Study Eye on OCT at Screening.  
5. BCV A ETDRS  score between 83 and 25 letters, inclusive, in the Study Eye at screening and 
reconfirmed at Day 1 . 
6. Decrease in vision in the Study Eye determined by the Investigator to be primarily the result 
of wAMD.  
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
33 In cases where both eyes are eligible, the eye with the worse BCVA at the Screening Visit will 
be selected as the Study Eye. If both eyes are eligible and  have the same BCVA, the decision of 
which eye to select as the Study Eye will be made by the Investigator. Only one eye per participant can participate in the study .  
5.1.2 General Inclusion Criteria  
7. Capable of giving signed informed consent as described in Appendix 1, which  includes 
compliance with the protocols and restrictions listed in the informed consent form (ICF) and 
in this protocol. 
8. Male or female ≥50 years of age.  
9. For women of childbearing potential: agreement to remain as abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of <1% per year during the treatment period . 
Women of c
hildbearing potential must have a negative urine pregnancy test result within 28 
days prior to Day 1. If the urine pregnancy test is positive, it must be confirmed with a serum pregnancy test. 
a. A woman is considered of childbearing potential if she is postmenarcheal, has not 
reached a postmenopausal state ( ≥12 months of amenorrhea with no identified cause 
other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). The definition of childbearing potential may be adapted for alignment with local guidelines or requirements.  
b. Examples of contraceptive methods with a failure rate of <1% per year include 
bilateral tubal ligation, male sterilization, established, proper use of hormonal contraceptives that inhibit ovulation, hormone- releasing intrauterine devices and  
copper intrauterine devices. 
c. Contraception methods that do not result in a failure rate of <1% per year such as cap, diaphragm, or sponge with spermicide, or male or female condom with or without spermicide, are not acceptable.  
d. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. 
10. For men: agreement to remain abstinent or use contraceptive measures and agreement to 
refrain from donating sperm, as defined below: 
a. With female partners of childbearing potential, men must remain abstinent or use a 
condom plus an additional contraceptive method that together result in a failure rate of <1% per year during the treatment period  
 aft
er  the last dose of study drug. Men must refrain from 
donating sperm during this same time period. 
11. Ability and willingness to undertake all the scheduled visits and assessments. 

CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
34 5.2 Exclusion Criteria  
Participants are excluded from the study if any of the criteria in Sections 5.2.1 and 5.2.2 apply. 
5.2.1 Ocular  Exclusion Criteria  
Where applicable exclusion criteria will be confirmed or assessed by the independent, masked 
image Reading Center.   
1. BCV A of hand motion or worse in the non-Study Eye or non-physical presence of a non-
Study Eye (i.e., monocular). 
2. Active or suspected ocular or periocular infection or inflammation in either eye at Screening or on Day 1. 
3. CNV secondary to other causes in the Study Eye, including pathologic myopia, angioid streaks, prior trauma, ocular histoplasmosis, or others. 
4. Any history of macular pathology unrelated to AMD but affecting vision or contributing to subretinal or intraretinal fluid, such as central serous chorioretinopathy.  
5. Fibrosis or atrophy of >50% of the lesion size and/or involving the foveal center of the Study Eye at Screening.  
6. Subretinal blood affecting the foveal center of the Study Eye and/or more than 50% of the lesion size at Screening.  
7. Retinal pigment epithelium tear or rip in the Study Eye at Screening  or on Day 1. 
8. Any approved or investigational treatment for neovascular AMD (other than oral vitamin supplements) in the Study Eye at any time. 
9. Prior macular laser (e.g., thermal laser or photodynamic therapy laser) in the Study Eye. 
10. Any history or evidence of a concurrent ocular condition present in the Study Eye, that in the opinion of the Investigator could require either medical or surgical intervention or affect macular edema or alter visual acuity during the study (e.g., vitreomacular traction, epiretinal membrane). 
11. History of cataract surgery and/or minimally invasive glaucoma surgery (MIGS) in the Study Eye within 2 months of screening. 
12. History of Yttrium- Aluminum Garnet (YAG) laser capsulotomy in the Study Eye within 2 
months of screening. 
13. Uncontrolled glaucoma (defined as intraocular pressure ≥ 25 mmHg despite treatment with antiglaucoma medication) in the Study Eye. 
14. History of glaucoma-filtering surgery (trabeculectomy or tube shunt) in the Study Eye.  
15. History of retinal detachment or treatment or surgery for retinal detachment in the Study Eye. 
16. History of uveitis in either eye.  
17. Significant media opacities, including cataract, in the Study Eye that might interfere with visual acuity, assessment of safety, OCT  or fundus photography.  
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
35 18. Cataract in the Study Eye that in the judgment  of the Investigator is expected to require 
surgical extraction within 12 months of screening. 
19. Aphakia in the Study Eye. 
20. Prior vitrectomy in the Study Eye. 
21. Prior intraocular or periocular steroids in the Study Eye. 
22. Current vitreous hemorrhage or history of vitreous hemorrhage in the Study Eye within 3 
months of Screening. 
23. History of corneal transplant in the Study Eye. 
5.2.2 General Exclusion Criteria  
24. Women who are pregnant or lactating or intending to become pregnant during the study  
25. Recent history  (within the 6 months prior to screening) of myocardial infarction, stroke, 
transient  ischemic attack, acute congestive heart failure or any acute coronary event .  
26. History of a medical condition that, in the judgment of the Investigator, would preclude scheduled study visits, completion of the study, or a safe administration of investigational product. 
27. History of hypersensitivity to any component of KSI-301, aflibercept, ophthalmic dye (fluorescein), dilating drops, or any of the anesthetic or antimicrobial preparations used during the study, as assessed by the Investigator. 
28. Participation in an investigational study within 30 days prior to the screening visit that involved treatment with any investigational drug (excluding vitamins and minerals) or device, except for non -therapeutic ophthalmic imaging devices . 
29. Active cancer within the 12 months prior to Screening except for appropriately treated carcinoma in situ of the cervix, non- melanoma skin cancer, and prostate cancer with a 
Gleason score of <6 and stable prostate-specific antigen for >12 months. 
30. Treatment with systemic anti-VEGF therapeutics within 90 days prior to Screening. 
31. Uncontrolled blood pressure defined as a systolic value ≥180 mmHg or diastolic value ≥100 mmHg while at rest at Screening or on Day 1. 
• If a participant’s initial blood pressure measurement exceeds these values, up to two additional readings may be taken later the same day or on a different day during the screening period. If a participant’s blood pressure is controlled by antihypertensive medications, the participant must be on a stable medication regimen  continuously for 21 days prior to Day 1. 
 
5.3 Lifestyle Considerations  
No specific lifestyle restrictions are required.   
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
36 5.4 Screen Failures  
Screen failures are defined as participants who consent to participate in the clinical study but are 
not subsequently randomly assigned to study intervention. A minimal set of screen failure information is required to ensure transparent reporting of screen failure participants to meet the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to respond to queries from regulatory authorities. Minimal information includes demography, screen failure details, eligibility criteria, and  any serious adverse event s (SAE) caused by a 
protocol-mandated intervention that occur during the screening period. 
Participants who do not meet eligibility criteria within the 21-day screening period will not be 
eligible for randomizatio n and will be considered  ‘screen -failed ’. However, a participant may be 
re-screened  up to one additional time at the discretion of the Investigator and in consultation with 
the Sponsor. When re-screening, the participant must be re-consented if more than 30 days have elapsed since the date of the last informed consent. In the event of re-screening, screening procedures need not be repeated if they fall within the 21-day screening window. If the re-screening occurs outside the 21-day window, all assessments performed at the initial screening visit should be repeated during the re- screening  visit except f luorescein angiogram (FA). If the 
re-screening visit is more than 8 weeks after the original screening visit, FA  should be repeated. 
For a re-screening visit occurring fewer than 8 weeks after the original screening visit, although a 
new FA will not be required, the previously acquired FA will need to be re- submitted to the 
Reading C enter labeled with the new participant  number, along with the new screening images 
from the other modalities. This will ensure that all images from the participant are properly labeled, kept within the same directory and that eligible transmission numbers a nd audit trails  are 
maintained . 
When  re-screening  tests  and procedures  have been  completed  and results  are available indicating  
the participant  is eligible  for study participation,  the participant  may  be enrolled.  When  re-
screening  a participant , a new  screening/ enrollment number will be generated  by IRT  system  to 
ensure there is  an audit trail for the screen -failed  participant .  
5.5 Criteria for Temporarily Delaying  Enrollment  
Inclusion/Exclusion criteria will be assessed at Screening and on Day 1 to determine a 
participant’s  eligibility for the study.  
If a participant meets all eligibility criteria ( Sections 5.1 and 5.2) at the Screening visit but does 
not meet the BCVA eligibility criterion due to expected variability and fluctuation in the BCVA value when they return for the planned Day 1 visit, the Sponsor will allow the participant to return one additional time to reassess the BCVA , provided the assessment still occurs within the 
21-day screening window. This repeat measurement for Day 1 visit (Repeat Day 1) is  not 
considered a rescreen. Women of childbearing potential who return for a Repeat Day 1 Visit must have a negative pregnancy test during the Repeat Day 1 Visit (i.e., the pregnancy test must 
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
37 be performed and documented as negative on the same day as randomization/first injection). 
Day 1 and Repeat Day 1 Visit data shall be used in the eCRF and IRT as follows: 
• eCRF : In the event that a participant has a Repeat Day 1 Visit, data from assessments 
conducted at the planned  randomization (Day 1) visit shall be clearly documented in the 
participant’s source data. If the participant  meets the eligibility criteria at the  Repeat Day 
1 visit, all data for assessments performed at that visit are entered into the eCRF under Day 1 and the original non-qualifying data will be entered as Unscheduled Visit assessments. 
• IRT: In the event that a participant has a Repeat Day 1 Visit  and is eligible  for this study, 
the BCVA and  SD-OCT values from the Repeat Day 1 visit must be used for participant  
randomization into the IRT system. If the participant  does not  meet eligibility at the 
Repeat Day 1 visit, the participant  must be recorded as a screen failure (Section 5.4) in 
the IRT system at that time.  
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
38 6.0 STUDY INTERVENTION(S) AND CONCOMITANT THERAPY 
Study intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study participant according to the study protocol. 
6.1 Study Intervention(s) Administered 
Study interventions are summarized in  Table 2 . For full information  regarding the administration 
of study intervention and the contents of the kit , refer to the Pharmacy Manual . For additional 
information regarding the administration of aflibercept, refer to the  approved prescribing 
information for aflibercept in your country, such as the Summary of Product Characteristics 
(SmPC)  or U.S. Prescribing Information (USPI) . The full instructions for administration of sham 
are described in the Pharmacy Manual.  
  
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
39 Table 2:  Protocol KS301P107: Study Interventions  
Group  Name  A B A or B  
Intervention Name  KSI-301 5  mg Aflibercept 2  mg Sham  
Type  Biological medicinal 
product  Biological medicinal 
product  Sham  
Dose Formulation  Sterile liquid for intravitreal 
injection in single -use vials  Sterile liquid for intravitreal 
injection in single -use vials 
or prefilled syringes  Empty vial  
Unit Dose Strength(s)  mg/mL (based on 
antibody mass)  40 mg/mL  N/A 
Dosage Level(s)  5 mg  2 mg (50  µL) N/A 
Route of Administration  Intravitreal injection  Intravitreal injection  Sham  injection  
Use Experimental  Active control  Sham  (to maintain study 
masking)  
IMP and NIMP  IMP IMP NIMP  
Sourcing  Provided centrally by the 
Sponsor  Provided centrally by the 
Sponsor  Provided centrally by the 
Sponsor  
Storage  In the original packaging, as 
provided, until the time of 
use. Store at 2 -8°C before 
use.  In the original packaging, as 
provided, until the time of use. Store at 2 -8°C before 
use.  In the original packaging, as 
provided, until the time of use. Store at 2 -8°C before 
use.  
Packaging and Labeling  KSI-301 will be provided in 
vials that will be labeled as 
required per country 
requirement . Aflibercept will be provided 
in vials or prefilled syringes 
that will be labeled as 
required per country requirement . Sham will be provided in 
vials that will be labeled as 
required per country 
requirement . 
Reconstitution and Handling  KSI-301 is an aqueous 
solution that is provided in vials and filled into syringes by unmasked site personnel without reconstitution or dilution.  
 Aflibercept  is an aqueous 
solution that is provided in vials and filled into syringes by unmasked site personnel without reconstitution or 
dilution  or provided in 
prefilled syringes . 
 Sham is provided as empty 
glass vials, which will 
remain empty throughout the 
sham treatment procedure. A 
sham injection mimics an intravitreal injection. It 
involves pressing the blunt end of an empty syringe, without a needle, against an anesthetized eye. 
Current/Former  
Name(s) or Alias(es)  N/A Eylea  N/A 
 
6.2 Preparation/Handling/Storage/Accountability 
6.2.1 Preparation, Handling, and Storage 
Study interventions (KSI-301 and aflibercept) are aqueous solutions provided in vials (or 
prefilled syringes for aflibercept) and filled into syringes by unmasked site personnel without reconstitution or dilution. 

CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
40 Study drug kits must be stored in a secure refrigerator at a controlled temperature of 2°C to 8°C. 
All study drug vials or prefilled syringes (for aflibercept) should be stored in the original packaging, as provided, until the time of use.  
Please refer to Pharmacy Manual for additional instructions. 
6.2.2 Study Intervention Accountability and Reconciliation  
Study intervention packaging will be overseen by the Sponsor or their designee and bear a label 
with the identification required by local law, the protocol number, drug identification, and dosage. The packaging and labeling of the study medication will be in accordance with local regulations. 
The investigational site will acknowledge receipt of the study intervention, to confirm the 
shipment condition and content. Any damaged shipments will be replaced. Upon arrival of the study intervention at the site, site personnel will complete the following: 
• Check the shipment for damage. 
• Verify proper identity, quantity, integrity of seals and temperature conditions. 
• Report any deviations or product complaints to the Sponsor or their designee upon discovery. 
Any study intervention under investigation for integrity or temperature excursion should be quarantined in the IRT , and not used until the final assessment by the Sponsor or its designee. 
The Investigator or designee must confirm appropriate temperature conditions have been maintained during transit for all study treatment received and any discrepancies are reported and resolved before use of the study treatment. 
Only participants enrolled in the study may receive study intervention and only authorized site 
staff may supply or administer study intervention. All study intervention must be stored in a secure, environmentally controlled, and monitored (manual or autom ated) area in accordance 
with the labeled storage conditions with access limited to the Investigator and authorized site staff.  
The Investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study intervention accountability, reconciliation, and record maintenance (i.e., receipt, reconciliation, and final disposition records). 
Further guidance and information for the final disposition of unused study interventions are 
provided in the Pharmacy Manual.  
The pharmacist responsible for dispensing study treatment, or the designated site personnel, will select the correct study intervention as assigned through the IRT. Instructions for the preparation of KSI-301, aflibercept, or sham for administration, mandatory materials to be used, and pretreatment and post- treatment procedures are detailed in the Pharmacy Manual.  
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
41 For more detailed information on the formulation, preparation, and handling of KSI-301, 
aflibercept, and sham, see the Pharmacy Manual.  
6.3 Measures to Minimize Bias: Randomization and Masking  
6.3.1 Randomization  
All participants will be centrally assigned to a randomized study intervention using an IRT  
system. Before the study is initiated, login information and directions for the IRT will be 
provided to each site.  
Study intervention will be dispensed at the study visits as summarized in the SoA ( Section 1.3). 
6.3.2 Masking and Unmasking  
This is a double-masked study. There must be a minimum of two investigators per site to fulfill 
the masking requirements of this study, as follows: 
• Masked Evaluating Physician(s) : At least one Investigator will be designated as the 
evaluating physician who will be masked  to participants’ treatment assignments and will 
evaluate all ocular assessments  (other than the immediate post-injection assessments done by 
unmasked personnel, as described below).  
• Unmasked Treating Physician(s) : At least one other Investigator will be designated as the 
treating (injecting) physician who will be unmasked to participants’ treatment assignments 
and will administer study intervention (KSI -301, aflibercept, or sham) . This physician or an 
unmasked assistant will also conduct the immediate post- injection assessments , including 
tonometry, in the Study Eye (Section 8.1.4). The unmasked t reating physician and unmasked 
staff must not divulge treatment assignment to anyone. 
As shown in Section 6.1, t here are three study interventions : (1) KSI -301 (the investigational 
medicinal product); (2) aflibercept (the active comparator); and (3) sham (for which an injection 
procedure is simulated but not actually performed). All three  study interventions are provided in 
unmasked vials or prefilled syringes within masked cartons (also referred to as kits) , as follows:  
• Masked Cartons : All study interventions are provided in cartons that are identical in 
appearance and weight, making them indistinguishable from each other. 
Each carton is labeled  with an identical carton label  that includes a unique kit number. The 
IRT system  will direct site personnel which specific carton to pull from inventory and use for 
a specific participant  at a given visit based on the unique kit number printed on the carton 
label and that participant ’s treatment at that given visit.  
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
42 • Unmasked Vials  or Prefilled Syringes  Within the Masked Cartons : Owing to differences 
among vials, syringes, dose-preparation procedures, and treatment procedures that cannot be 
masked, the treating (injecting) physician is unmasked to study treatment as are any assistants to the treating (injecting) physician . Only unmasked site staff  are allowed to open 
the masked cartons. 
Participants, study site personnel (except for the t reating physician(s), assistant(s), and 
pharmacist if any), the designated evaluating physician(s), central Reading Center personnel, and the Sponsor and its agents will be masked to treatment assignment.  
The visual acuity  (VA) examiner (performing the refraction, BCVA examination) will be 
masked to the participant treatment assignment. The BCVA examiner will have no access to the 
VA scores of a participant’s previous visits and may have access only to a participant’s refraction  data from previous visits.  
A participant’s treatment assignment will not be unmasked until the end of the study or unless medical treatment of the participant depends on knowing the study treatment the participant received. Emergency code break is available to the Investigator online in the IRT. If unmasking is necessary for participant management (for example, in the case of a serious adverse event for which participant management might be affected by knowledge of the treatment assignment), the Investigator will be able to break the treatment code by accessing the IRT  system. Treatment 
codes must not be broken except in emergency situations. If the Investigator wishes to know a participant’s treatment assignment for any other, non-emergency reasons, he or she should consult with the M edical Monitor. The Investigator should document and provide an explanation 
for any non-emergency unmasking (for example, accidental unmasking). 
For regulatory reporting purposes and if required by local health authorities, the Sponsor or its 
agents (e.g., c ontract research organization ( CRO ) pharmacovigilance personnel) will break the 
treatment code for all serious, unexpected suspected adverse reactions (SUSARs) that are considered by the Investigator or Sponsor to be related to study intervention. The participant may continue to receive treatment, and the Investigator, participant, and Sponsor or CRO personnel, except for the pharmacovigilance personnel who must have access to participant treatment assignments to fulfill their roles, will remain masked to treatment assignments.  
Additional information regarding masking and unmasking will be outlined in the Masking Manual.  
6.4 Study Intervention Compliance  
Only participants enrolled in the study may receive study treatment and only ophthalmologists who have experience administering intravitreal injections may administer study treatment.  
The unmasked Investigator is responsible for administering the correct dose of KSI-301 or aflibercept and for the sham administration , according to the study protocol. The date and time of 
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
43 each dose administered in the clinic will be recorded in the source documents and e lectronic case 
report form  (eCRF ). To avoid medication dispensing errors, the study intervention, study 
participant  and Study Eye identification will be confirmed at the time of dosing by a member of 
the unmasked study site team . 
6.5 Dose Modification 
Participants can only receive the specified dose for the intervention group, as follows: 
A. KSI-301: 5 mg    
B. Afl
ibercept : 2 mg  (50 µL ).  
Alterations of the dosage are not allowed.  
6.6 Continued Access to Study Intervention after the End of the Study  
After participants complete their final follow -up visit or discontinue from the study prematurely, 
they will return to standard of care treatment at the discretion of their Treating Physician. The 
Sponsor will not provide continued access to study treatment following the end of the study or the end of each participant’s study treatment period. 
6.7 Treatment of Overdose  
For this study, any dose of KSI -301 greater than 5 mg  or aflibercept greater than 2 mg  at a single 
study visit will be considered an overdose. 
The Sponsor does not recommend any specific treatment for an overdose.  In the event of an accidental overdose, the Investigator/t reating physician should: 
• Contact the Medical Monitor immediately.  
• Evaluate the participant to determine, in consultation with the Medical Monitor, 
whether additional steps should be taken. 
• Closely monitor the participant for any AE/SAE. 
• Document the quantity of the excess dose. 
In addition to overdosing, an increased injection volume may  cause an increase in intraocular 
pressure. In case of overdose, intraocular pressure should be monitored and if deemed necessary 
by the T reating Physician, adequate treatment should be initiated, including performing pressure 
lowering procedures ( i.e., anterior chamber paracentesis) . 
6.8 Concomitant Therapy 
Use of all concomitant medications will be recorded in the participant’s eCRF , except for 
medications  required for carrying out procedures in the SoA ( Section 1.3) (e.g., dilating drops, 

CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
44 anesthetic s, antiseptic, fluorescein, etc .) related to  this study. Concomitant medications  will 
include all prescription drugs, herbal products, vitamins, minerals, and over the counter ( OTC ) 
medications  as used by the participant within 30 days prior to Day 1 through Week 52. Any 
changes in concomitant medications also will be recorded in the participant’s eCRF.  
Any concomitant medication deemed necessary for the welfare of the participant during the 
study may be given at the discretion of the Investigator. However, it is the responsibility of the Investigator to ensure that all  relevant  details regarding the medication are recorded in the eCRF. 
Participants who use oral contraceptives, hormone-replacement therapy, or other maintenance therapy should continue their use. 
In case the fellow e ye (non-Study Eye)  requires anti-VEGF treatment during the conduct of the 
study, the participant may be treated at the discretion of the Investigator and according to the 
standard of care in the respective country. The treatment of the fellow  eye ( non-Study Eye)  may 
be implemented at any time once the Day 1 injection has been administered. Anti- VEGF 
treatment  for the fellow eye, including the date of each administration, must be documented as a 
concomitant medication on the appropriate e CRF. If the fellow eye requires treatment during the 
same visit as the Study Eye, the Study Eye should be treated first, and the fellow eye should be treated by the unmasked physician to preserve masking.  
The Medical Monitor should be contacted if there are any questions regarding concomitant or 
prior therapy. 
6.8.1 Prohibited Therapy  
At the discretion of the Investigator, participant s may start or continue to receive all medications 
and standard treatments administered for other conditions, except for the following : 
• Investigational therapies in the non-Study Eye, 
• Intravitreal anti-VEGF drugs in the Study Eye other than study- assigned aflibercept or 
KSI-301 until all assessments are completed at Week 48 , 
• Systemic anti- VEGF  therapy, 
• Concurrent use of intravitreal or periocular steroids or steroid implants in the Study Eye, 
• Concurrent use of macular photocoagulation or photodynamic therapy with verteporfin in 
the Study Eye, and 
• Investigational treatment with any drug (other than vitamins and minerals) or device . 
Participants  whose medical care requires use of a prohibited therapy must have study treatment 
interrupted or be discontinued from the study in order to receive that therapy. After discussion with the Sponsor, participants  whose study treatment has been interrupted but no longer need a 
prohibited therapy may resume study treatment. 
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
45 6.8.2 Supportive Care for Adverse Events  
Supportive care for the known potential risks associated with anti- VEGF treatment and KSI -301 
(summarized in  Table 1 ) should be as per the standard of care in the respective country. No 
specific prophylactic therapies are recommended.  
 
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
46 7.0 DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  
7.1 Discontinuation of Study Intervention  
Participants may withdraw from the study at any time and for any reason without prejudice to 
their future medical care by the Investigator or at the study site. Every effort should be made to keep participants in the study.  
If study intervention is discontinued, an end -of-treatment visit should occur 28 +/- 7 days after 
study treatment is discontinued or before a new treatment regimen begins. Participants  who 
discontinue study drug should NOT  be considered withdrawn from the study. Unless they 
withdraw consent or there is additional risk to the participant , part icipants  who have discontinued 
study treatment should be encouraged to stay in the study and undergo as many scheduled visits 
as possible, with emphasis on the W eeks 40, 44, and 48 (primary endpoint) visits.  
The reasons for study treatment discontinuation and/or withdrawal from the study (study discontinuation) will be recorded on the appropriate eCRF. 
A participant may be withdrawn from the study for any of the following reasons: 
1. The participant is noncompliant with the protocol. 
2. The participant has a serious or intolerable adverse event(s) (AE[s]) that in the 
Investigator’s opinion requires withdrawal from the study. 
3. The participant has symptoms or an intercurrent illness not consistent with the protocol requirements or that justify withdrawal.  
4. The participant is lost to follow -up. 
5. Any medical condition that the Investigator or Sponsor determines may jeopardize the participants’ safety if they remain in the study.  
6. The participant withdraws consent, or the Investigator or Sponsor decides to discontinue the participant’s participation in the study.  
7. Pregnancy.  
The Investigator will also withdraw a participant if the Sponsor terminates the study. Upon 
occurrence of a serious or intolerable AE, the Investigator will confer with the Sponsor. If a participant is discontinued because of an AE, the event will be followed until it is resolved, or no additional improvement is expected by the Investigator (based on a follow-up period of not less than 3 months). Any participant may withdraw his or her consent at any time. 
7.1.1 Treatment Interruption and/or Discontinuation due to Adverse Events or 
Concomitant Procedures  
Study treatment interruption and/or participant discontinuation from the study treatment due to 
certain adverse events or concomitant procedures in the Study Eye will be determined using the 
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
47 criteria provided in Table 3 . If any  of these are met, treatment will be interrupted (or 
discontinued if applicable) and notification will be sent to the M edical Monitor. Treatment may 
be resumed after resolution of the adverse event and upon agreement with both the Investigator 
and M edical Monitor. The reason for study treatment interruption or discontinuation should be 
recorded on the appropriate eCRF and, if applicable, on the a dverse e vent eCRF.  
Table 3:  Protocol KS301P107: Treatment Interruption Criteria  
Event  
(MedDRA Preferred Term)  Study Treatment Interruption Criteria  
Vision loss  Interrupt study treatment for treatment -related  decrease of ≥30 letters in 
BCVA in the Study Eye  compared with the most recent prior visit.  
Intraocular inflammation  Interrupt study treatment if any active intraocular inflammation is present  in 
the Study Eye . 
Intraocular surgery  Interrupt study treatment for intraocular surgery in the Study Eye , for 
example cataract surgery.  
Treatment may resume no earlier than 10  days after uncomplicated cataract 
surgery, provided there is no evidence of post operative  intraocular 
inflammation. For complicated cataract surgery or following other 
intraocular surgery, study treatment may be resumed as determined by the Investigator following discussion with the Medical Monitor.   
Elevated intraocular pressure  Interrupt study treatment if the pre -injection IOP is >30 mmHg in the Study 
Eye. 
Retinal tear or break  Interrupt study treatment if a retinal tear or break is present in the Study Eye .  
Treatment may be resumed no earlier than 10 days after successful laser 
retinopexy, as determined by the I nvestigator.  
Retinal detachment or macular hole  Interrupt study treatment if rhegmatogenous retinal detachment or Stage 3 or 
Stage 4 macular hole occurs in the Study Eye . 
Treatment may be resumed no earlier than 14 days after successful 
treatment, as determined by the I nvestigator, following discussion with the 
Medical Monitor.  
Active infection  Interrupt study treatment if infectious cellulitis, conjunctivitis, keratitis, 
scleritis, or endophthalmitis occurs in or around either eye.  
Infections should be treated as per the local standard of care.  
 
7.2 Participant Discontinuation/Withdrawal from the Study  
Participant s should be strongly encouraged to stay in the study and undergo as many scheduled 
visits as possible, with emphasis on the Week s 40, 44, and 48 visits. However, participants are 
free to withdraw from the study or study treatment at any time upon request. Participant  
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
48 participation in the study may be stopped at any time at the discretion of the Investigator or at the 
request of the Sponsor. 
Participant s who discontinue study treatment or active participation in the study will no longer 
receive study intervention . When a participant  discontinues from study treatment or active 
participation in the study, the reason(s) for study treatment discontinuation or withdrawal shall 
be recorded by the Investigator or designee on the relevant page of the eCRF . Whenever 
possible, all participant s who discontinue study treatment or withdraw from the study 
prematurely will undergo an Early Termination visit. Participant s who fail to return for final 
assessments must be contacted by the site by phone and in writing to  obtain follow-up. 
If a participant exits early from the study between visits, the Investigator or designee must attempt to contact the participant  and advise the participant to return for a final visit to complete 
the exit procedures. If the participant  is unable or unwilling to return for the E arly Termination  
visit, the ‘date of exit’ will be the date that the participant was last seen at the site or contacted by other communication.  
If the participant withdraws consent for disclosure of future information, the Sponsor may retain 
and continue to use any data collected before such a withdrawal of consent. 
If a participant withdraws from the study, he/she may request destruction of any samples taken 
and not tested, and the Investigator must document this in the site study records. 
7.3 Lost to Follow-up 
A participant  will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by the study site. 
The following actions must be taken if  a participant fails to return to the clinic for a required 
study visit: 
• The site must attempt to contact the participant and reschedule the m issed visit as soon as 
possible and counsel the participant  on the importance of maintaining the assigned visit 
schedule and ascertain whether  the participant wishes to and/or should continue in the 
study. 
• Before a participant  is deemed lost to f ollow-up, the Investigator or designee must make 
every effort to regain contact with the participant  (where possible, three telephone calls 
and, if necessary , a certified letter to the participant’s last known mailing address or local 
equivalent methods) and discuss the situation with the Sponsor . These contact attempts 
should be documented in the participant’s medical record . 
• Should the participant  continue to be unreachable, he/she will be considered to have 
withdrawn from the study.  
Discontinuation of specific sites or of the study as a whole are handled as part of Appendix 1. 
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
49 8.0 STUDY ASSESSMENTS AND PROCEDURES  
• Before undertaking any study procedures, all potential participant s will sign an ICF . 
Participant s will have the opportunity to have any questions answered before signing the 
ICF. The Investigator or designee must address all questions raised by the participant . 
The Investigator or designee will also sign the ICF.   
• Study procedures and their timing are summarized in the SoA ( Section 1.3). Assessments 
performed in the event of an unscheduled safety visit ( Appendix 5) are at the discretion 
of the Investigator. Adherence to the study design requirements, including those specified 
in the SoA, is essential and required for study conduct. All screening evaluations must be completed and reviewed to confirm that potential participants meet all eligibility criteria. The Investigator will maintain a screening log to record details of all participants 
screened and to confirm eligibility or record reasons for screening failure, as applicable. 
• Protocol waivers or exemptions are not allowed.  
• Immediate safety concerns should be discussed with the Sponsor immediately upon 
occurrence or awareness to determine if the participant should continue or discontinue study intervention. 
8.1 Efficacy A ssessments  
Planned time points for all efficacy  assessments are provided in the SoA ( Section 1.3). 
8.1.1 Medical History  and Demographic Data 
Medical history (general  and ophthalmic) includes clinically significant diseases, surgeries  and 
reproductive status. All medications (e.g., prescription drugs, OTC drugs, herbal or homeopathic 
remedies, nutritional supplements) used by the participant regularly or within 30 days preceding Day 1  will be recorded . A full ocular history including prior ocular treatments will be noted. 
Demographic data will include age, sex, ethnic origin (also referred to as self- reported race and 
ethnicity in some regions of the world), and smoking status.  
8.1.2 Ophthalmic  Exams  
Unless otherwise noted, ophthalmic assessments are captured for the Study Eye only. 
Slit-lamp examination will include  the following:  
• Inspection of the eyelids, 
• Inspection of the cornea, 
• Examination of the anterior chamber, 
• Examination of the pupil, 
• Examination of the iris , 
• Inspection of the lens, 
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
50 • Inspection of the vitreous body, and 
• Inspection of the retina and optic disc. 
Dilated indirect ophthalmoscopy will include examination of the peripheral retina. 
Tonometry shall be conducted as part of the ophthalmic exam. The method of IOP measurement 
(such as Goldmann tonometry or Tonopen) must remain the same throughout the study for each 
participant. Pre -injection tonometry should be performed prior to pupil dilation.  
Participants will be instructed to report any signs or symptoms of intraocular inflammation (uveitis) or endophthalmitis such as pain, photophobia, redness, or reduced vision.  
8.1.3 Injection Procedure  
The unmasked injecting I nvestigator must be qualified and trained in administering intravitreal 
injections and follow standard injection procedures in adherence to specific institutional or local 
policies associated with intravitreal  injections. Aseptic technique must be observed by clinic staff 
involved in the assembly of the injection tray, study intervention preparation, anesthetic preparation, and study treatment administration. To minimize the risk of infection, the periocular skin, eyelid and conjunctiva of the Study Eye mus t be disinfected , as outlined in the Syringe 
Preparation and Injection Procedure Guidelines found in the Pharmacy Manual.  
The unmasked injecting Investigator will choose one of the acceptable methods of ocular 
anesthesia on a per participant basis. Subconjunctival anesthesia is recommended (but not required) to maximize participant comfort. In order to maintain masking, the selected method of anesthesia for an individual participant  must remain constant for the duration of the trial and at 
all visits irrespective of the study treatment assigned during the study visit (KSI-301, a flibercept 
or sham).  
Please refer to  the Pharmacy  Manual  for additional instructions on IMP preparation and 
administration . 
8.1.4 Post-injection Assessments in the Study Eye  
Within 5 minutes after the injection, check vision for count fingers or hand motion.  
• Tonometry (between 30 and 50 minutes after injection):  
If the IOP is >30 mmHg or has increased by ≥ 10 mmHg from pre- injection, the IOP will 
be measured again at 60−80 minutes post -injection. If there are no safety concerns, the 
participant will be permitted to leave the clinic. If the IOP value is of concern to the 
Investigator, the participant will remain in the clinic and will be managed in accordance with the Investigator’s clinical judgment. The latest post-injection IOP measured (prior to any intervention for increased IOP, if applicable) will be recorded on the post- treatment 
IOP eCRF.  
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
52 Additional specifications and instructions regarding acceptable equipment imaging and imaging 
techniques will be provided by the Reading Center. 
8.2 Safety  Assessments 
Planned time points for all safety assessments are provided in the SoA ( Section 1.3). 
8.2.1 Vital Signs  
The following vital signs will be assessed with the participant in a seated position after resting 
for 5 minutes: blood pressure (BP), pulse rate, and body temperature. H eight  and weight will be 
recorded at the screening visit only . 
8.2.2 Clinical Safety Laboratory Assessments 
See Appendix 2 for the list of clinical laboratory tests to be performed and refer to the SoA 
(Section 1.3) for the timing and frequency. 
The Investigator or designee must review the laboratory report, document this review, and record 
any clinically significant changes occurring during the study as an  AE. The laboratory reports 
must be filed with the source documents.  
Abnormal laboratory findings associated with the underlying disease are not considered 
clinically significant unless judged by the Investigator to be more severe than expected for the participant's condition. 
All laboratory tests with values considered clinically significantly abnormal during participation 
in the study or within 30 day s after the last dose of study intervention should be repeated until 
the values return to normal or baseline or are no longer considered clinically significant by the Investigator or M edical Monitor. 
• If clinically significant values do not return to normal/baseline within a period of time judged reasonable by the Investigator, the etiology should be identified, and the Sponsor notified . 
• All protocol-required laboratory tes ts, as defined in Appendix 2, must be conducted in 
accordance with the SoA  (Section 1.3). 
• If laboratory values from non-protocol-specified laboratory tes ts performed at the 
institution’s local laboratory require a change in participant management or are considered clinically significant by the Investigator (e.g., SAE or AE or dose modification), then the results must be recorded. 
8.2.3 Pregnancy T esting  
Participant samples for pregnancy testing will be taken at the Screening and Day 1 visits and then monthly in women of childbearing potential only as specified in the SoA ( Section 1.3).  
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
53 Prior to enrollment in the study, female participant s of childbearing potential and male 
participant s must be advised of the importance of avoiding pregnancy or partner pregnancy, 
respectively, during the trial and the potential risks associated with an unintentional pregnancy. 
Contraceptive and barrier guidance and collection of pregnancy information is described in Appendix 6. 
8.3 Adverse Events , Serious Adverse Events , and Other Safety Reporting  
The definitions of AEs  and SAEs  are provided in Appendix 3. 
AEs will be reported by the participant (or, when appropriate, by a caregiver or surrogate ). 
The Investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible for following 
up AEs that are serious, considered related to the study intervention or study procedures, or that caused the participant to discontinue the study (see Section 7 ). 
The method of recording, evaluating, and assessing causality of AEs and SAEs and the procedures for completing and transmitting SAE reports are provided in Appendix 3. 
8.3.1 Time Period and Frequency for Collecting AE and SAE Information  
After informed consent has been obtained but prior to initiation of study intervention, only SAEs 
caused by a protocol-mandated assessment  should be reported. After initiation of study 
intervention (Day 1), all AE and SAE information will be collected  until the final safety follow-
up visit at Week 52 or the ET visit, if applicable.  
All SAEs will be recorded and reported to the Sponsor or designee immediately and under no circumstance should this exceed 24 hours, as indicated in Appendix 3. The I nvestigator will 
submit any updated SAE data to the Sponsor within 24 hours of it being available. 
Investigators are not obligated to actively seek information on AE s or SAE s after conclusion of 
the study participation. However, if the Investigator learns of any SAE, including a death, at any 
time after a participant has been discharged from the study, and he/she considers the event to be reasonably related to the study intervention or study participation, the Investigator must promptly notify the Sponsor. 
8.3.2 Method of Detecting AEs and SAEs  
Care will be taken not to introduce bias when detecting AEs and/or SAEs. At every study visit, 
open -ended and nonleading verbal questioning of the participant is the preferred method to 
inquire about AE occurrences . The  participant  will also be asked if they have been hospitalized, 
had any accidents, used any new medications, or changed concomitant medication regimens (both prescription and OTC medications). 
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
54 In addition to participant  observations, AEs identified from any study data (e.g., laboratory 
values, ophthalmic examination findings) or identified from review of other documents that are 
relevant to participant safety will be documented on the AE page in the eCRF. 
The method of recording, evaluating, and assessing causality of AE and SAE and the procedures 
for completing and transmitting SAE reports are provided in Appendix 3. 
8.3.3 Follow- up of AEs and SAEs  
After the initial AE/SAE report, the Investigator is required to proactively follow each 
participant at subsequent visits/contacts. All SAEs  and AEs of special interest (as defined in 
Section 8.3.6), will be followed until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow -up (as defined in Section  7.3). Further information on follow-
up procedures is provided in Appendix 3. 
8.3.4 Regulatory Reporting Requirements for SAEs  
Prompt notification by the Investigator to the Sponsor of a n SAE is essential so that legal 
obligations and ethical responsibilities toward  the safety of participants and the safety of a study 
intervention under clinical investigation are met.  The Sponsor has a legal responsibility to notify 
both the local regulatory authority and other regulatory agencies about the safety of a study 
intervention under clinical investigation. The Sponsor will comply with country -specific 
regulatory requirements relating to safety reporting to the regulatory authority, Institutional Review Boards (IRB)/Independent Ethics Committees (IEC), and investigators. 
An Investigator who receives an Investigator safety report describing an SAE or other specific 
safety information (e.g., summary or listing of SAEs) from the Sponsor will review and then file 
it along with the I B and will notify the IRB/IEC, if appropriate according to local requirements. 
Investigator safety reports must be prepared for SUSARs  according to local regulatory 
requirements and Sponsor policy and forwarded to investigators as necessary. 
8.3.5 Pregnancy  
During the study, female and male participant s are to be instructed to contact the Investigator 
immediately if they suspect they might be pregnant or if their partner becomes pregnant, 
respectively , and details will be collected. Additional urine or serum pregnancy testing may be 
performed during the study at the discretion of the Investigator, or in accordance with local requirements or regulations.  
Pregnancy is not regarded as an AE unless there is a suspicion that an investigational product 
may have interfered with the effectiveness of a contraceptive medication. Any pregnancy that occurs during study participation must be reported using the same pr ocedures as an SAE on a 
Sponsor prepared form. To ensure participant safety, each pregnancy must be reported to the Sponsor or its designee immediately (within 24 hours) after learning of its occurrence. The 
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
55 pregnancy must be followed up to determine outcome (including spontaneous miscarriage, 
elective termination, normal birth, or congenital abnormality) and status of mother and child, even if the participant was discontinued from the study. Pregnancy complications and elective terminations for medical reasons must be reported as an AE or SAE. Spontaneous miscarriages must be reported as an SAE. 
Any SAE occurring in association with a pregnancy, brought to the Investigator ’s attention after 
the participant  has completed the study, and considered by the Investigator as possibly related to 
the study treatment, must be promptly reported to the Sponsor. Pregnancy is considered a criterion  for discontinuation from the study, please refer to Section 7.1 
for additional information. Contraceptive and barrier guidance and collection of pregnancy 
information is described in Appendix 6. 
8.3.6 Adverse Events of Special Interest  
An adverse event of special interest (AESI) is one of scientific and medical concern specific to 
the Sponsor’s product or program where ongoing monitoring and rapid communication by the Investigator to the Sponsor may be appropriate. These AEs  may be serious or non-serious. 
Applicable AEs  may require additional investigation in order to characterize and understand, and 
depending upon the nature of the event, rapid communication by the Sponsor to other parties may also be required. 
These AESIs must be reported by the Investigator using the same mechanism ( Electronic data 
capture (EDC ) or fax) and time  frame  (i.e., within 24 hours after learning of the event) as 
described previously for SAEs . The AESIs include the following: 
• AEs resulting from medication error, including overdose, incorrect dose, incorrect drug, 
incorrect administration , or incorrect kit. 
• AEs with sight-threatening potential, meeting one or more of the following criteria: 
o Causes a decrease ≥ 30 letter in BCVA compared with the last visual acuity  
assessment ; 
o It is associated with severe intraocular inflammation (i.e., endophthalmitis, Grade 4 aqueous flare/aqueous cells, Grade 4 vitreous haze/vitreous cells; see Appendix 4 for grading scales); or 
o Requires surgical intervention to prevent permanent loss of sight. 
• Cases of potential liver injury ( Appendix 7). 
As with all AEs occurring in a study participant , a decision will be made by the Investigator 
concerning additional exposure to study treatment and further participation in the study. 
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
56 8.4 Pharmacokinetics  
To understand the pharmacokinetic ( PK) profile of the study intervention following intravitreal 
injection  (i.e., systemic  exposure), plasma concentration of KSI-301 will be measured. For 
exploratory purposes,  
 Plasma samples of comparator may also be analyzed for systemic PK and systemic 
biomarke
rs. 
Blood samples of approximately 4 mL will be collected from participants for measurement of 
plasma  concentrations of KSI -301, as specified in the SoA  (Section 1.3). 
Instructions for the collection and handling of biological samples will be included in the C entral 
Laboratory M anual. The actual date and time  when  each sample is collected will be recorded.  
8.5 Genetics  and/or Pharmacogenomics 
Genetics and/or pharmacogenomics are not evaluated in this study. 
8.6 Biomarkers  
Blood samples that were collected from participants for systemic PK analysis ( Section 8.4) may 
also be analyzed for measurement of plasma biomarkers , as specified in the SoA ( Section 1.3).  
Instructions for the collection and handling of biological samples will be provided by the C entral 
Laboratory M anual . The actual date and time when each sample is collected will be recorded.  
8.7 Immunogenicity Assessments  
Blood samples of approximately 4 mL will be collected for detection and confirmation of anti -
drug antibodies (ADAs) , as well as  assays to further  characteriz e the anti -drug antibodies as 
specified in the SoA ( Section 1.3). Additionally, plasma  samples should also be collected and 
evaluated at the final visit from participants who discontinued study intervention or were 
withdrawn from the study as per the SoA .  
The detection and characterization of ADAs  to KSI-301 will be performed using a validated 
assay method . Plasma  samples will be screened for antibodies binding to KSI- 301 and the titer  of 
confirmed positive samples will be reported. Speci ficity  analyses may be performed to further 
characterize the immunogenicity of KSI-301. Anti- KSI-301 antibodies may be further 
characterized and/or evaluated for their ability to neutralize the activity of the study 
intervention(s) (neutralizing antibodies or NAB s). All samp les collected for detection of 
antibodies to study intervention will also be evaluated for KSI -301 plasma concentration to 
enable interpretation of the antibody data.  

CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
57 Samples may be stored for a maximum of 5 years (or according to local regulations) following 
the last participant’s last visit for the study at a facility selected by the Sponsor to enable further analysis of immune responses to KSI -301.  
8.8 Health Economics or Medical Resource Utilization and Health Economics 
These parameters are not evaluated in this study. 
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
58 9.0 STATISTICAL CONSIDERATIONS  
9.1 Study Hypothesis 
Intensive t reatment with KSI -301 5 mg will provide a non-inferior mean change in BCVA 
compared to aflibercept 2  mg in participants with visual impairment due to wAMD. 
9.2 Sample Size Determination  
The sample size for the comparison of the change in BCVA between treatment group A 
(KSI-301 5 mg once every 4 weeks ) and treatment group B (aflibercept 2  mg once every 8 weeks 
after 3 initial monthly injections ) from Day 1 to the average of Weeks 40, 44, and 48 is based on 
a non-inferiority approach. The following assumptions were made in order to calculate the sample size:  
• Overall type I error rate of 0.025. Testing at the 0.025 level for non- inferiority 
corresponds to setting 95% CIs; 
• Statistical power of ≥90% ; 
• Standard deviation of the distribution of change in visual acuity from baseline of 
 letters ; 
• The ma
ximum, clinically acceptable true difference for KSI -301 to be considered non-
inferior, or the “non- inferio rity margin ,” ; 
• The statistical test used to compare the two treatment groups using ETDRS BCVA data collected up to Week 48 is an independent t-test on the mean change in visual acuity from baseline (Day 1); and  
• Lost to follow-up/dropout rate of approximately . 
The sa
mple size calculated using the above assumptions is approximately 500 participants (2 50 
per treatment group).   
 
 
 
 
 
Note : “en
rolled” means a participant's agreement to participate in a clinical study following 
completion of the informed consent process, screening , and the Day 1 visit. Potential participants 
who are screened for the purpose of determining eligibility for the study, but who do not participate in the study, are not considered enrolled, unless otherwise specified by the protocol.  
 

CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
59 9.3 Analysis Sets 
For the purpose of analysis, the following analysis sets are defined:  
Population  Description  
Rando mized /intent to treat (ITT)  
set The ITT  set will be comprised of all participants  who were randomized in to 
one of  the study groups . 
For analyses based on this population, participants  will be grouped 
according to the  study intervention assigned at randomization.  
Evaluable /per protocol (PP)  set The PP  set will comprise  all ITT participants who fulfill all 
inclusion/exclusion criteria and have no significant protocol deviations that 
are expected to have a significant impact on the assessment of efficacy, including lack of compliance with study treatment, missing data , and having 
taken any prohibited medication. All analyses using the PP  set will group 
participants according to the  study intervention  they actually received . 
Safety  set The safety set will comprise a ll participants randomly assigned to study 
intervention and who receive  at least one  dose of study intervention. 
Participants will be analyzed according to the intervention they actually received.  
Pharmacokinetic /biomarker /ADA -
evaluable  set The PK/biomarker evaluable data set will comprise  all participants in the 
ITT set with at least one post- Day 1 evaluable sample. The ADA- evaluable 
data set will consist of all participants in the ITT set  with at least one 
evaluable sample. 
 
9.4 Statistical Analyses 
The study SAP will fully specify the statistical methodology and reporting for all aspects of the 
planned analyses. The SAP will be finalized prior to database lock and executed thereafter, and it will include a more technical and detailed description of the statistical analyses described in this section. This section is a summary of the planned statistical analyses of the most important endpoints including primary and key secondary endpoints.  
Additional unplanned analyses may be required after all planned analyses have been completed, 
and additional analyses of key efficacy metrics may be performed between the primary and final analyses to support marketing applications for various jurisdictions. Any unplanned analyses will be clearly identified in the clinical study report.  
9.4.1 General Considerations 
At baseline (Day 1), participants will be randomized 1:1 into one of t wo treatment groups: 
A. KSI-301 5 mg : once
  every four (4) weeks from Day 1 to Week 44; or 
B. Aflibercept  2 mg (50  µL): three (3) monthly doses at Day 1, Week 4, and Week 8 , 
followed by once every 8 weeks (Q8W) until Week 44. Participants randomized to the 

CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
60 aflibercept treatment group will receive a sham injection at each visit that aflibercept is 
not administered (i.e., at Weeks 12, 20, 28, 36, and 44).   
This study consists of one efficacy and safety assessment period ( Section 1.2), as follows: 
• Day 1 to Week 52, which consists of the treatment period  (Day 1 through Week 44), 
4-week efficacy and safety period (to Week 4 8), and a final 4- week safety assessment at 
Week 52 (8 weeks after the last dose).  
Using ETDRS BCV A data collected up to Week 48, t he treatment groups will be compared using 
a non- inferiority analysis, with a margin . Confide nce intervals will be 
100(1- 2 α) or 95% CI . If the null hypothesis of inferiority is rejected, testing for superiority will 
be performed. That is, if the lower confidence limit for the difference in mean BCV A lies within (-4.5, ∞), the null hypothesis of inferiority will be rejected, and non- inferiority will be 
established. Furthermore, if the lower confidence limit lies within (0, ∞), superiority will be established.   
Analysis of data will be performed when all participants have either completed the Week 52 visit or have discontinued from the study, all data have been entered into the database, cleaned and verified as appropriate, and the database has been locked.  
Details of all preplanned analyses, including imputation approaches for the handling of missing data, subgroup analyses (for example, across key demographic and ocular baseline characteristics), and sensitivity analyses , will be included in the SAP. The results of all analyses 
detailed in the SAP will appear in the final clinical study report.   
9.4.2 Primary Endpoint(s)  
The primary endpoint is defined as the mean change in ETDRS BCVA from baseline (Day 1) to Week s 40, 44, and 48. The primary assessment of efficacy will be based on a pairwise 
comparison in mean change in BCVA between treatment group A (KSI -301 5 mg ) and treatment 
group B ( aflibercept 2  mg). 
Unless stated otherwise, all analyses described will be performed on the ITT Population.  
Analysis of the primary endpoint data will be performed when the following occur: 
• all participants have either completed the Week 4 8 visit or have discontinued from the 
study prior to the Week 48 visit, whichever comes later;  
• all data up to and including the Week 48 visit have been entered into the database, and 
have been cleaned, and verified as appropriate; and  
• the database for the primary analysis locked.  
If there are no imbalances on important prognostic factors at baseline, a simple independent t- test 
and corresponding CIs will be used for evaluation of treatment differences. If there are 

CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
61 imbalances in key prognostic factors at baseline (e.g., BCVA) generalized linear models or other 
statistical models (such as mixed effects models) will be used to estimate the difference in mean change in BCVA between treatment groups and CIs derived from the corresponding standard error of the estimate. These models will also include indicator variables for stratification variables. An alpha level of 0.025 will be used for hypothesis testing and CIs will be 100(1- 2α) 
or 95% CI. If the null hypothesis of inferiority is rejected, testing for superiority will be performed.  
Full details on the statistical testing procedures along with supplementary and sensitivity 
analyses will be provided in the SAP. 
9.4.3 Secondary E ndpoint(s)  
Key secondary endpoints will be assessed at Week 48 (for efficacy) or Week 52 (for safety):  
• Mean change in BCVA (ETDRS Letters) from baseline (Day 1) by visit over time.  
• Proportion of participants who gain ≥5, ≥10 and ≥15 ETDRS letters from baseline 
(Day  1) by visit over time. 
• Proportion of participants who lose ≥5, ≥10 and ≥15 ETDRS letters from baseline (Day  1) by visi t over time.  
• Proportion of participants with BCVA Snellen equivalent of 20/40 or better from baseline (Day 1) over time.  
• Proportion of participants with BCVA Snellen equivalent of 20/200 or worse from baseline (Day 1)  over time.  
• Mean change in OCT CST from baseline (Day 1)  to Week 4 8 and over time.  
• Incidence of ocular and systemic AEs up to Week 52. 
• Systemic anti-drug antibody status over time (in the ADA-evaluable population). 
• Systemic pharmacokinetic profile (i.e. , systemic exposure) over time (in the 
PK-evaluable population). 
Unless stated otherwise, all analyses described will be performed on the ITT Population.  
For continuous key secondary efficacy endpoints, the between-group changes from baseline in 
BCVA at each time point will be computed and compared using t- tests, generalized linear 
models, mixed effects models, or other approaches as documented in the SAP. In addition, comparisons between groups determined by fixed effects of interest will be performed by analysis of covariance ( ANCOVA) in which the dependent variable is the continuous variable of 
interest at the specified time point, the covariate is the ba seline value of the variable of interest. 
Treatment group as well as stratification variables will be entered as fixed effects. Results of the t-test will be reported as 95% CI s for within group mean change from baseline. Results of 
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
62 ANCOVA will be reported as 95% CIs  for the difference in adjusted means for the grouping 
determined by the fixed effects of interest. 
For categorical variables, the number and percentage of responders will be presented by 
treatment group for each time period and will be evaluated among treatment groups using chi-square tests of proportions supplemented with logistic regression models.  
Additional endpoints and f ull details  on statistical considerations  will be provided in the SAP. 
9.4.4 Tertiary/ Exploratory E ndpoint(s)  
Exploratory endpoints will be described in the SAP. 
9.4.5 Safety Analy sis 
The safety analysis (using the safety set described in Section 9.3) will use  outcomes of all 
participants who were exposed to study treatment regardless of adherence to the protocol or 
treatment outcome. Safety analyses will be conducted concurrently with efficacy analyses.  
In addition to analyses of ocular safety events, all reported AEs  will be listed by MedDRA term, 
frequency, severity, association to the study therapy, and treatment group. By- treatment 
incidence rates will also be calculated for the treatment groups. For certain AEs, per- injection 
rates will also be described.  
9.4.6 Pharmacokinetic and Biomarker Analysis 
PK analyses will be outlined in the PK Analysis Plan ; potential exploratory biomarker analyses 
will be outlined in a B iomarker A nalysis P lan. 
9.5 Interim Analys is 
There is no interim analysis planned for this study.  
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
63 10.0 APPENDICES WITH SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS  
Appendix 1:  Regulatory, Ethical, and Study Oversight Considerations 
Appendix 2:  Clinical Laboratory Tests  
Appendix 3:  AEs and SAEs: Definitions and Procedures for Recording, Evaluating, Follow-up, 
and Reporting 
Appendix 4:  Grading Scale for Assessment of Anterior Chamber Flare or Cells, Vitreous Cells 
or Haze  
Appendix 5: Unscheduled Safety Assessment Visits 
Appendix 6:  Contraceptive and Barrier Guidance Appendix 7:  Liver Safety  
Appendix 8:  Protocol Amendment History  
 
 
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
64 10.1 Appendix 1:  Regulatory, Ethical, and Study Oversight Considerations 
10.1.1 Regulatory and Ethical Considerations 
This study will be conducted in accordance with the protocol and with the following: 
• Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines  
• Applicable ICH Good Clinical Practice (GCP) Guidelines  
• Applicable laws and regulations 
The protocol, protocol amendments, ICF, Investigator ’s Brochure, and other relevant documents 
(e.g., advertisements) must be submitted to an IRB/IEC by the Investigator and reviewed and 
approved by the IRB/IEC before the study is initiated. 
Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate hazard to study participants.  
The Investigator will be responsible for the following: 
• Providing written summaries of the status of the study to the IRB/IEC annually or more 
frequently in accordance with the requirements, policies, and procedures established by the IRB/IEC ; 
• Notifying the IRB/IEC of SAEs or other significant safety findings as required by IRB/IEC procedures ; and  
• Providing oversight of the conduct of the study at the site and adherence to requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies, and all other applicable local regulations. 
10.1.2 Financial Disclosure  and Financial Obligations  
Investigators are required to provide financial disclosure information to allow the Sponsor to submit the complete and accurate certification or disclosure statements  to the appropriate 
regulatory authorities . In addition, Investigators must provide to the Sponsor a commitment to 
promptly update this information if any relevant changes occur during the investigation and for 1 year following the completion of the study. 
Neither the Sponsor nor their CRO partner is financially responsible for additional testing or 
treatment of any medical condition that may be detected during the screening process. In addition, in the absence of specific arrangements, neither the Sponsor nor their CRO are financially responsible for further treatment of the participant’s disease . 
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
65 10.1.3 Informed Consent Process  
The Investigator or his/her representative will explain the nature of the study to the participant 
and answer all questions regarding the study. 
Participants must be informed that their participation is voluntary. Participants will be required to 
sign a statement of informed consent that meets the requirements of 21 CFR 50, local regulations, ICH guidelines, Health Insurance Portability and Account ability Act (HIPAA) 
requirements, where applicable, and the IRB/IEC or study center. 
The medical record must include a statement that written informed consent was obtained before 
the participant was enrolled in the study and the date the written consent was obtained. The authorized person obtaining the informed consent must also sign the I CF. 
If required by the IRB/EC, participants must be re -consented to the most current version of the 
ICF(s) during their participation in the study. 
A copy of the ICF(s) must be provided to the participant. Participants who are re- screened  are required to sign a new ICF if it has been more than 30 days 
from the initial consent date . 
The ICF will contain a separate section that addresses the use of remaining samples for optional 
exploratory research . The Investigator or authorized designee will explain to each participant the 
objectives of the exploratory research. Participants will be told that they are free to refuse to participate and may withdraw their consent at any time and for any reason during the s torage 
period. A separate signature will be required to document a participant's agreement to allow any remaining specimens to be used for exploratory research. Participants who decline to participate in this optional research will not provide this separate signature. 
10.1.4 Data Protection 
Participants will be assigned a unique identifier by the Sponsor. Any participant records or 
datasets that are transferred to the Sponsor will contain the identifier only; participant names or any information which would make the participant identifiable will not be transferred. 
The participant must be informed that his/her personal study- related data will be used by the 
Sponsor in accordance with local data protection law. The level of disclosure must also be 
explained to the participant who will be required to give consent for their data to be used as described in the informed consent.  
Participant  medical information obtained by this study is confidential, and disclosure to third 
parties other than those noted below is prohibited. All laboratory specimens, evaluation forms, 
reports, and other records will be identified in a manner designed to maintain participant  
confidentiality. All records will be kept in a secure storage area with limited access. Upon the 
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
66 participant ’s permission, medical information may be given to his or her personal physician or 
other appropriate medical personnel responsible for his or her welfare. 
The participant must be informed that his/her medical records may be examined by Clinical 
Quality Assurance auditors or other authorized personnel appointed by the Sponsor, by appropriate IRB/IEC members, and by inspectors from regulatory authorities. 
All information provided by the Sponsor, verbally and in writing, is confidential. The 
Investigator agrees not to disclose any such information without prior written permission of the Sponsor. This document may be disclosed to study personnel under the Investigator’s supervision and to the IRB under the condition that they also agree to maintain its confidentiality. Any supplemental information (e.g., protocol amendment) that may be added to this document is confidential and must also be handled accordingly. The information obtained from the Sponsor may be disclosed to obtain informed consent from participants who wish to participate in the study. 
Study documents provided by the Sponsor (protocols, IB, etc.) will be stored appropriately to 
ensure their confidentiality.  
The Investigator and all employees and co-workers involved with this study may not disclose or 
use for any purpose other than performance of the study any data, record, or other unpublished, 
confidential information disclosed to those individuals for the purpose of the study. Prior written agreement from the Sponsor or its designee must be obtained for the disclosure of any said confidential information to other parties. 
10.1.5 Committees Structure  
10.1.5.1 Independent Data Monitoring Committee  
An Independent Data Monitoring Committee (IDMC) will monitor the study conduct and safety 
on an ongoing basis. Members of the IDMC will be external to the Sponsor and will follow a charter that outlines the IDMC membership and responsibilities, the timing of IDMC meetings, the content of the analysis report for the IDMC meetings, and the communication with the 
Sponsor. The IDMC can recommend changes to the conduct of the study based on the evaluated data and may recommend stopping the study early for safety reasons. Nominal Ty pe I error 
penalties for IDMC reviews will be outlined in the SAP.
 
10.1.6 Data Quality Assurance 
All participant data relating to the  study will be recorded on printed or eCRF unless transmitted 
to the Sponsor or designee electronically (e.g., laboratory data). The Investigator is responsible for verifying that data entries are accurate and correct by physically or electronically signing the eCRF.  
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
67 The Investigator must permit study -related monitoring, audits, IRB/IEC review, and regulatory 
agency inspections and provide direct access to source data documents. 
Monitoring details describing strategy (e.g., risk -based initiatives in operations and quality such 
as Risk Management and Mitigation Strategies and Analytical Risk -Based Monitoring), methods, 
responsibilities and requirements, including handling of noncompliance issues and monitoring 
techniques (central, remote, or on-site monitoring) are provided in the Monitoring Plan. 
The Sponsor or designee is responsible for the data management of this study including quality 
checking of the data.  
The Sponsor assumes accountability for actions delegated to other individuals (e.g., CROs ). 
Records and documents, including signed ICFs, pertaining to the conduct of this study must be retained by the Investigator for 10 years  after study completion unless local regulations or 
institutional policies require a longer retention period. No records may be destroyed during the retention period without the written approval of the Sponsor. No records may be transferred to another location or party without written notification to the Sponsor. 
10.1.7 Source Documents  
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. Source documents are filed at the I nvestigator’s site.  
Data reported on the eCRF or entered in the eCRF that are transcribed from source documents 
must be consistent with the source documents or the discrepancies must be explained. The Investigator may need to request previous medical records or transfer records, depending on the study. Also, current medical records must be available. 
The Investigator must maintain accurate documentation (source data) that supports the 
information entered in the e CRF.  
Study monitors will perform ongoing source data verification to confirm that data entered into 
the eCRF by authorized site personnel are accurate, complete, and verifiable from source documents; that the safety and rights of participants are being protected; and that the study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements. 
10.1.8 Study and Site Start and Closure  
First Act of Recruitment  
The study start date is the date on which the clinical study will be open for recruitment of 
participants.  
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
68 Study/Site Termination  
The Sponsor or designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of the Sponsor. Study sites will be closed upon study completion. A study site is considered closed when all required documents and study supplies have been collected and a study site closure visit has been performed. 
The Investigator may initiate study  site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination. Reasons for the early closure of a study site by the Sponsor or Investigator may include but are 
not limited to:  
For study termination: 
• Discontinuation of further study intervention development 
For site termination:  
• Failure of the Investigator to comply with the protocol, the requirements of the IRB/IEC or 
local health authorities, the Sponsor's procedures, or GCP guidelines 
• Inadequate or no recruitment (evaluated after a reasonable amount of time) of participants by 
the Investigator 
If the study is prematurely terminated or suspended, the Sponsor shall promptly inform the 
investigators, the IECs/IRBs, the regulatory authorities, and any CRO (s) used in the study of the 
reason for termination or suspension, as specified by the applicable regulatory requirements. The Investigator shall promptly inform the participant  and should assure appropriate participant  
therapy and/or follow-up. 
10.1.9 Publication Policy  
The results of this study may be published or presented at scientific meetings. If this is foreseen, 
the Investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. 
This allows the Sponsor to protect proprietary information and to provide comments. 
The Sponsor will comply with the requirements for publication of study results. In accordance 
with standard editorial and ethical practice, the Sponsor will generally support publication of multi- center  studies only in their entirety and not as individual site data. In this case, a 
coordinating Investigator will be designated by mutual agreement. 
Authorship will be determined by mutual agreement and in line with International Committee of 
Medical Journal Editors authorship requirements. 
  
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
75 10.4 Appendix 4: Grading S cale for Assessment of A nterior Chamber Flare or Cells, 
Vitreous Cells or Haze.  
10.4.1 Grading Scales for Anterior Chamber Cells or Flare  
The SUN Working Group  Grading Scale for Anterior Chamber  Cells  
Grade  Cells in Field1 
0 <1 
0.5+ 1-5 
1+ 6-15 
2+ 16-25 
3+ 26-50 
4+ >50 
Abbreviations: SUN = Standardization of uveitis nomenclature . 
14 Field size is a 1  mm by  1 mm slit beam . 
Source: (Jabs 2005) 
 
The SUN Working Group Grading Scale for Anterior Chamber Flare  
Grade  Cells in Field1 
0 None  
1+ Faint  
2+ Moderate (iris and lens details clear)  
3+ Marked (iris and lens details hazy)  
4+ Intense (fibrin or plastic aqueous)  
Abbreviations: SUN = Standardization of uveitis nomenclature . 
15 Field size is a 1  mm by  1 mm slit beam . 
Source: (Jabs 2005) 
 
  
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
76 10.4.2 Grading Scale for Vitreous Cells  
Source : (Foster 2013) 
 
10.4.3 Grading Scale for Vitreous Haze 
Score Description  Clinical Findings  
0 Nil None  
1 Minimal  Posterior pole clearly visible  
2 Mild  Posterior pole details slightly hazy  
3 Moderate  Posterior pole details very hazy 
4 Marked  Posterior pole details barely visible  
5 Severe Fundal details not visible  
Source:  (Nussenblatt 1985) 
 Grade  Description  
0 No Cells  
½+  1-10 
1 + 11-20 
2 + 21- 30 
3 + 31 - 100 
4+ Greater than 100  
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
77 10.5 Appendix 5: Unscheduled Safety Assessment Visits  
Assessments performed at unscheduled safety visits are at the discretion of the Investigator. The 
following safety assessments are recommended:  
• Vital signs (blood pressure, respiration rate, pulse, temperature);  
• Hematology, serum chemistry panel, and coagulation panel; 
• Best corrected visual acuity  (BCVA) ; 
• Slit-lamp  examination (both eyes); 
• Tonometry (both eyes); 
• Indirect ophthalmoscopy (both eyes); 
• Adverse events;  
• Concurrent ocular procedures; and 
• Concomitant medications.  
The causality of adverse events is to be evaluated by a masked physician. 
  
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
78 10.6 Appendix 6: Contraceptive and Barrier Guidance  
10.6.1 Definitions  
Wom en of Childbearing Potential (WOCBP) 
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanently sterile (see below).  
If fertility is unclear (e.g., amenorrhea in adolescents or athletes) and a menstrual cycle cannot be confirmed before first dose of study intervention, additional evaluation should be considered. 
Women in the following categories are not considered WOCBP: • Premenarchal  
• Premenopausal female with one of the following: 
- Documented hysterectomy  
- Documented bilateral salpingectomy  
- Documented bilateral oophorectomy 
For individuals with permanent infertility due to an alternate medical cause other than the above, 
(e.g., Müllerian agenesis, androgen insensitivity), Investigator discretion should be applied to determining study entry. 
Note: Documentation can come from the site personnel’s: review of the participant’s medical 
records, medical examination, or medical history interview. 
Postmenopausal F emale  
A postmenopausal state is defined as no menses for 12 months without an alternative medical 
cause.  
A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormone replacement therapy (HRT). However, in the absence of 12 months of amenorrhea, confirmation with more than one FSH measurement is required. The Screening Visit FSH will be processed using the chemistry tube and the Day 1 FSH will need to be collected separately and sent to the central lab for analysis.  A pregnancy test is required unti l both FSH measurements have been 
collected and results have been received that verify the post -menopausal state of the female 
participant .  
Females  on HRT and whose menopausal status is in doubt will be required to use one of the non-
estrogen hormonal highly effective contraception methods if they wish to continue their HRT 
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
79 during the study. Otherwise, they must discontinue HRT to allow confirmation of 
postmenopausal status before study enrollment. 
10.6.2 Contraception Guidance  
Participants who use oral contraceptives, HRT , or other maintenance therapy should continue 
their use.  
• For women of childbearing potential: agreement to remain as abstinent (refrain from 
heterosexual intercourse) or use contraceptive methods that result in a failure rate of <1% per year during the treatment period and  
  
o Examp
les of contraceptive methods with a failure rate of <1% per year include 
bilateral tubal ligation, male sterilization, established, proper use of hormonal 
contraceptives that inhibit ovulation, hormone- releasing intrauterine devices and 
copper intrauterine devices. 
o Contraception methods that do not result in a failure rate of <1% per year such as cap, diaphragm, or sponge with spermicide, or male or female condom with or without spermicide, are not acceptable.  
o The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant . Periodic 
abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. 
• For men: agreement to remain abstinent or use contraceptive measures and agreement to 
refrain from donating sperm, as defined below: 
o With female partners of childbearing potential, men must remain abstinent or use 
a condom plus an additional contraceptive method that together result in a failure rate of <1% per year during the treatment period  
 the l
 ast dose of study intervention. Men must 
refrain from donating sperm during this same time period. 
10.6.3 Collection of Pregnancy Information 
Female participants who become pregnant  
• The Investigator will collect pregnancy information on any female participant who becomes 
pregnant while participating in this study. The initial information will be recorded on the 
appropriate form and submitted to the Sponsor within 24 hours of learning of a participant's pregnancy.  

CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
80 • The participant will be followed to determine the outcome of the pregnancy. The Investigator 
will collect follow -up information on the participant and the neonate,  and the information 
will be forwarded to the Sponsor. Generally, follow-up will not be required for longer than 6 to 8 weeks beyond the estimated delivery date. Any termination of pregnancy will be reported, regardless of fetal status (presence or absence of anomalies) or indication for the procedure. 
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or elective termination of a pregnancy for medical reasons will be reported as an AE or SAE.  
• A spontaneous abortion (occurring at <22 weeks gestational age) or still birth  (occurring at 
>22 weeks gestational age) is always considered to be an SAE and will be reported as such.  
• Any post-study pregnancy related SAE considered reasonably related to the study intervention by the Investigator will be reported to the Sponsor, as described in Section 8.3.4. While the Investigator is not obligated to actively seek this information in former study 
participants, he or she may learn of an SAE through spontaneous reporting. 
• Any female participant who becomes pregnant while participating in the study will discontinue study intervention or be withdrawn from the study. 
Male participants with partners who become pregnant  
• The Investigator will attempt to collect pregnancy information on any male participant’s 
female partner who becomes pregnant while the male participant is in this study. This applies only to male participants who receive any study intervention. 
• After obtaining the necessary signed informed consent from the pregnant female partner directly, the Investigator will record pregnancy information on the appropriate form and submit it to the Sponsor within 24 hours of learning of the partner’s pregnancy. The female partner will also be followed to determine the outcome of the pregnancy. Information on the status of the mother and child will be forwarded to the Sponsor. Generally, the follow- up will 
be no longer than 6 to 8 weeks following the estimated delivery date. Any termination of the pregnancy will be reported regardless of fetal status (presence or absence of anomalies) or indication for the procedure.  
 
  
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
81 10.7 Appendix 7: Liver Safety  
Investigators must report to the Sponsor immediately (within 24 hours) the following laboratory 
findings as an AE indicative of severe liver injury (as defined by Hy’s Law): 
• Treatment -emergent ALT or AST more than 3 times the Upper Limits of Normal (ULN) in 
combination with an elevated total bilirubin (more than 2 times the ULN)  
• Treatment -emergent ALT or AST more than 3 times the U LN in combination with clinical 
jaundice 
The most appropriate diagnosis or (if the diagnosis cannot be established) the abnormal 
laboratory values should be recorded in the eCRF. 
   
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
83 11.0 REFERENCES  
1. Brown DM, Kaiser PK, Michels M , et al. 2006. Ranibizumab versus verteporfin for 
neovascular age-related macular degeneration. New England Journal of Medicine, 355: 
1432-44. 
2. Campochiaro PA. 2015a. Molecular pathogenesis of retinal and choroidal vascular diseases. Progress in Retinal and Eye Research, 49: 67-81. 
3. Campochiaro PA, Clark WL, Boyer DS , et al. 2015b. Intravitreal Aflibercept for Macular 
Edema Following Branch Retinal Vein Occlusion. Ophthalmology, 122: 538-44. 
4. Cheung N, Mitchell P, and Wong TY. 2010. Diabetic retinopathy. The Lancet, 376: 124-36. 
5. Chew EY, Clemons TE, Agron E , et al. 2014. Ten -year follow -up of age- related macular 
degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmol, 132: 272-7. 
6. Foster CSVitale AT. 2013. Diagnosis & Treatment of Uveitis (JP Medical Ltd).  
7. Gragoudas ES, Adamis AP, Cunningham Jr ET , et al. 2004. Pegaptanib for neovascular 
age-related macular degeneration. New England Journal of Medicine, 351: 2805-16. 
8. Heier JS, Brown DM, Chong V , et al. 2012. Intravitreal aflibercept (VEGF trap -eye) in 
wet age-related macular degeneration. Ophthalmology, 119: 2537-48. 
9. Holz FG, Sadda SR, Busbee B , et al. 2018. Efficacy and safety of lampalizumab for 
geographic atrophy due to age- related macular degeneration: Chroma and Spectri phase 3 
randomized clinical trials. JAMA ophthalmology, 136: 666-77. 
10. Homayouni M. 2009. Vascular endothelial growth factors and their inhibitors in ocular neovascular disorders. Journal of ophthalmic & vision research, 4: 105. 
11. Jabs D, Nussenblatt R, and Rosenbaum J. 2005. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. American Journal of Ophthalmology, 140: 509-16. 
12. Jaffe G, Kaiser P, Thompson D , et al. 2016. Visual acuity of eyes with early persistent 
retinal fluid from neovascular age- related macular degeneration in the VIEW studies. 
Ophthalmology, 123: 1856-64. 
13. Nguyen QD, Brown DM, Marcus DM , et al. 2012. Ranibizumab for diabetic macular 
edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology, 119: 789-801. 
14. Nussenblatt RB, Palestine AG, Chan C-C , et al. 1985. Standardizatlon of Vitreal 
inflammatory Activity in Intermediate and Posterior Uveitis. Ophthalmology, 92: 467-71. 
15. Rosenfeld PJ, Brown DM, Heier JS , et al. 2006. Ranibizumab for neovascular age- related 
macular degeneration. New England Journal of Medicine, 355: 1419-31. 
CONFIDENTIAL  Protocol KS301P107, Version 2.0 
 KSI-301 – Kodiak Sciences Inc. 
84 16. Rubio RGAdamis AP. 2016. 'Ocular angiogenesis: vascular endothelial growth factor and 
other factors.' in, Retinal Pharmacotherapeutics  (Karger Publishers).  
17. Schmidt-Erfurth U, Chong V, Loewenstein A , et al.  2014. Guidelines for the 
management of neovascular age -related macular degeneration by the European Society of 
Retina Specialists (EURETINA). British Journal of Ophthalmology, 98: 1144-67. 
18. Stewart MW, Rosenfeld PJ, Penha FM , et al. 2012. Pharmacokinetic rationale for dosing 
every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap -eye). Retina, 32: 434-57. 
19. Wong WL, Su X, Li X , et al. 2014. Global prevalence of age- related macular 
degeneration and disease burden projection for 2020 and 2040: a systematic review and meta -analysis. Lancet Glob Health, 2: e106-16. 
 